产品分类
NIBSC代理产品
发表时间：2025-07-10| 货号 | 品名 | 规格 |
| WY-NIBSC-SS-319/20 | FITC CD4 Positive Control Cells | 1EA |
| WY-NIBSC-00/410 | MAPREC assay of poliovirus type 1 (Sabin).100% 480-A, 525-C DNA(1st International Reference Preparation) | 1EA |
| WY-NIBSC-00/416 | Low Mutant Virus Reference for MAPREC assay of poliovirus type 1 (Sabin)(1st International Reference Preparation) | 1EA |
| WY-NIBSC-00/418 | MAPREC assay of poliovirus type 1 (Sabin) (1st International Standard) | 1EA |
| WY-NIBSC-00/422 | High Mutant Virus Reference for MAPREC assay of poliovirus type 1 (Sabin)(1st International Reference Preparation) | 1EA |
| WY-NIBSC-00/440 | Influenza Antiserum A/Singapore/1/57 (H2) | 1EA |
| WY-NIBSC-00/442 | Influenza anti B/Yamanashi/166/98 Serum | 1EA |
| WY-NIBSC-00/498 | Diphtheria Antitoxin Human IgG | 1EA |
| WY-NIBSC-00/500 | Botulinum Type A-E Antitoxin, Human Serum | 1EA |
| WY-NIBSC-00/542 | Influenza anti- A/Chick/Scotland/59 (H5N1) Serum | 1EA |
| WY-NIBSC-00/546 | Influenza Antigen B/Johannesburg/5/99 | 1EA |
| WY-NIBSC-00/548 | Influenza Antigen A/Singapore/1/57 (H2N2) | 1EA |
| WY-NIBSC-00/552 | Influenza Antigen A/Duck/Singapore-Q/F119-3/97 (H5N3) | 1EA |
| WY-NIBSC-00/556 | Influenza anti-B/Johannesburg/5/99/ Serum | 1EA |
| WY-NIBSC-00/572 | Interferon Beta (Human, rDNA, Glycosylated) (3rd International standard) | 1EA |
| WY-NIBSC-00/574 | Interferon Beta SER17 Mutein (Human, rDNA derived) | 1EA |
| WY-NIBSC-00/576 | Interferon Beta (Human, Fibroblast-derived, Glycosylated) | 1EA |
| WY-NIBSC-007SP | Human Anti-Pneumococcal capsule Reference Serum (1st International Standard) | 1EA |
| WY-NIBSC-01/412 | Anti-Meningococcal Immunotype L3,7,9 Monoclonal Antibody | 1EA |
| WY-NIBSC-01/420 | Interleukin-17 (Human rDNA derived)(WHO Reference Reagent) | 1EA |
| WY-NIBSC-01/450 | Influenza anti B/Guangdong/120/2000 Serum | 1EA |
| WY-NIBSC-01/452 | Influenza anti A/Panama/2007/99 (H3N2) HA serum | 1EA |
| WY-NIBSC-01/506 | Botulinum type F antitoxin, equine | 1EA |
| WY-NIBSC-01/508 | Botulinum type C antitoxin, equine | 1EA |
| WY-NIBSC-01/510 | Botulinum Antitoxin Equine Type D | 1EA |
| WY-NIBSC-01/512 | Botulinum type G antitoxin, equine | 1EA |
| WY-NIBSC-01/514 | Anti-Meningococcal Serosubtype P1.7 Monoclonal Antibody | 1EA |
| WY-NIBSC-01/538 | Anti-Meningococcal Serosubtype P1.16 mAb | 1EA |
| WY-NIBSC-01/546 | Influenza Antigen B/Guangdong/120/2000 | 1EA |
| WY-NIBSC-01/600 | Anti-Toxoplasma IgG, Human(International Standard) | 1EA |
| WY-NIBSC-01/602 | Anti-Parvovirus B19, plasma, human(2nd International Standard) | 1EA |
| WY-NIBSC-01/612 | Influenza Virus infectious B/Hawaii/10/01 | 1EA |
| WY-NIBSC-01/614 | Influenza Antigen A/New Caledonia/20/99 | 1EA |
| WY-NIBSC-02/102 | Influenza anti A/Panama/2007/99 Serum | 1EA |
| WY-NIBSC-02/144 | Anti-Meningococcal Serosubtype P1.15 mAb | 1EA |
| WY-NIBSC-02/148 | Anti-Meningococcal Serosubtype P1.4 mAb | 1EA |
| WY-NIBSC-02/178 | Anti-Meningococcal Serosubtype P1.2 mAb | 1EA |
| WY-NIBSC-02/180 | Anti-Meningococcal Serotype P2.2a mAb | 1EA |
| WY-NIBSC-02/182 | Anti-Japanese Encephalitis Virus Plasma, Human | 1EA |
| WY-NIBSC-02/184 | Anti-Japanese Encephalitis (Anti-JE) Virus Negative Control Plasma, Human | 1EA |
| WY-NIBSC-02/210 | HIV (antibody), 1st International Reference Panel | 1EA |
| WY-NIBSC-02/226 | IVIG negative control for use with IVIG + anti-D(WHO Reference Reagent) | 1EA |
| WY-NIBSC-02/228 | IVIG + anti-D for use with negative control IVIG(WHO Reference Reagent) | 1EA |
| WY-NIBSC-02/230 | Biotinylated Brad-5 (Bio-Brad-5) | 1EA |
| WY-NIBSC-02/232 | Tetanus Toxoid (Non-Adsorbed) | 1EA |
| WY-NIBSC-02/294 | Influenza Antiserum A/chick/Italy/1347/99 (H7N1) | 1EA |
| WY-NIBSC-02/308 | Anti-Meningococcal Serotype P3.4 mAb | 1EA |
| WY-NIBSC-02/310 | Anti-Meningococcal Serotype P3.15 mAb | 1EA |
| WY-NIBSC-02/318 | Botulinum Antitoxin Equine Type E | 1EA |
| WY-NIBSC-02/320 | Anti-Meningococcal Serosubtype P1.3 mAb | 1EA |
| WY-NIBSC-02/336 | Influenza Antigen A/New Caledonia/20/99 | 1EA |
| WY-NIBSC-02/338 | Influenza anti A/Panama/2007/99 Serum | 1EA |
| WY-NIBSC-02/342 | Protein C Plasma, Human(2nd International Standard) | 1EA |
| WY-NIBSC-03/104 | HTLV-1 (antibody) Monitor Sample | 1EA |
| WY-NIBSC-03/110 | Influenza anti B/Shangdong/9/97 Serum | 1EA |
| WY-NIBSC-03/114 | Anti-Meningococcal Serosubtype P1.1 mAb | 1EA |
| WY-NIBSC-03/124 | Thrombopoietin ( Human rDNA derived) | 1EA |
| WY-NIBSC-03/142 | Anti-Meningococcal Serosubtype P1.14 mAb | 1EA |
| WY-NIBSC-03/148 | Keratinocyte growth factor (KGF, FGF-7)(24-163)(1st WHO Reference Reagent) | 1EA |
| WY-NIBSC-03/150 | Keratinocyte Growth Factor (KGF,FGF-7)(1st WHO Reference Reagent) | 1EA |
| WY-NIBSC-03/152 | Anti-HPA-1a (International Standard) | 1EA |
| WY-NIBSC-03/164 | Anti-B minimum potency reference preparation(International Standard) | 1EA |
| WY-NIBSC-03/178 | Vitamin B12, Serum Folate and holoTC (International standard) | 1EA |
| WY-NIBSC-03/182 | Anti-Meningococcal Serotype P3.21 mAb | 1EA |
| WY-NIBSC-03/188 | Anti-A minimum potency reference preparation(International Standard) | 1EA |
| WY-NIBSC-03/190 | Anti-HPA-3a(minimum potency)(WHO Reference Reagent) | 1EA |
| WY-NIBSC-03/192 | Thyroid-Stimulating Hormone, Recombinant, Human, for Bioassay (1st International standard) | 1EA |
| WY-NIBSC-03/200 | Interleukin - 18 (Human rDNA derived)(WHO Reference Reagent) | 1EA |
| WY-NIBSC-03/210 | Anti-Meningiococcal Serosubtype P1.6 mAb | 1EA |
| WY-NIBSC-03/212 | Influenza anti A/Wyoming/03/03 Serum | 1EA |
| WY-NIBSC-03/220 | Influenza Antigen A/Wyoming/03/03 | 1EA |
| WY-NIBSC-03/224 | Anti-Meningococcal Serosubtype P1.10 mAb | 1EA |
| WY-NIBSC-03/226 | Anti-Meningococcal Serosubtype P1.5 mAb | 1EA |
| WY-NIBSC-03/228 | Protein S, Plasma, Human(2nd International Standard) | 1EA |
| WY-NIBSC-03/236 | Anti-Meningococcal Serosubtype P1.13 mAb | 1EA |
| WY-NIBSC-03/242 | Influenza anti A/Puerto Rico/8/34 (H1N1) HA Serum | 1EA |
| WY-NIBSC-03/244 | Influenza Antiserum A/chick/Germany/N/49 | 1EA |
| WY-NIBSC-03/258 | Influenza Antigen A/New Caledonia/20/99 (IVR-116) | 1EA |
| WY-NIBSC-03/262 | Hepatitis B Surface Antigen subtype adw2, genotype A (International Reference Panel) | 1EA |
| WY-NIBSC-04/160 | Influenza Virus infectious NYMC X-147 | 1EA |
| WY-NIBSC-04/166 | TNF-related Apoptosis-Inducing Ligand (trail), Human, rDNA-derived(1st WHO Reference Reagent) | 1EA |
| WY-NIBSC-04/170 | Influenza Virus infectious A/Wellington/1/2004 | 1EA |
| WY-NIBSC-04/172 | Influenza Virus infectious IVR-139 | 1EA |
| WY-NIBSC-04/176 | Plasmodium falciparum DNA for NAT Assays(1st International Standard) | 1EA |
| WY-NIBSC-04/198 | Anti-Meningococcal Serotype P3.1 mAb | 1EA |
| WY-NIBSC-04/202 | Influenza Antigen B/ Jiangsu/10/2003 | 1EA |
| WY-NIBSC-04/224 | Factor V Leiden, Human gDNA, 1st International Genetic Reference Panel 2004 | 1EA |
| WY-NIBSC-04/228 | Influenza anti B/ Neuraminidase Serum | 1EA |
| WY-NIBSC-04/242 | Influenza anti B/Jiangsu/10/2003 HA Serum | 1EA |
| WY-NIBSC-04/246 | Anti-Meningococcal Serogroup W-135 mAb | 1EA |
| WY-NIBSC-04/248 | Anti-Meningococcal Serosubtype P1.19 mAb | 1EA |
| WY-NIBSC-04/252 | Protein C Concentrate, Human(1st International Standard) | 1EA |
| WY-NIBSC-04/260 | Influenza anti A/New Caledonia/20/99 HA Serum | 1EA |
| WY-NIBSC-04/262 | Influenza anti A/New York/55/2004 HA Serum | 1EA |
| WY-NIBSC-04/264 | Influenza Antigen A/New York/55/2004 (H3N2) (NYMC X-157) | 1EA |
| WY-NIBSC-05/102 | Influenza Virus infectious NYMC BX-7 | 1EA |
| WY-NIBSC-05/106 | Anti-HPA-1a minimum potency reagent(2nd WHO Reference reagent) | 1EA |
| WY-NIBSC-05/112 | Low Molecular Weight Heparin for Molecular Weight Calibration (2nd International Standard) | 1EA |
| WY-NIBSC-05/130 | Prothrombin Mutation G20210A, Human gDNA(1st International Genetic Reference Panel 2005) | 1EA |
| WY-NIBSC-05/134 | Anti-human papillomavirus type 16 serum (1st International Standard) | 1EA |
| WY-NIBSC-05/162 | Alpha-1-Antitrypsin, plasma derived(1st International standard) | 1EA |
| WY-NIBSC-05/190 | Anti Meningococcal Serosubtype P1.9 Monoclonal Antibody | 1EA |
| WY-NIBSC-05/192 | Anti Meningococcal Serotype P2.2b Monoclonal Antibody | 1EA |
| WY-NIBSC-05/234 | Influenza Antigen A/Hiroshima/52/2005 (H3N2) (IVR-142) | 1EA |
| WY-NIBSC-05/236 | Influenza anti A/Wisconsin/67/2005 Serum | 1EA |
| WY-NIBSC-05/252 | Influenza anti B Neuraminidase Serum | 1EA |
| WY-NIBSC-06/108 | Influenza Virus infectious IVR-116 | 1EA |
| WY-NIBSC-06/124 | Monoclonal Antibody for Serotyping Bordetella pertussis Fimbrial Antigen 2 (1st International Standard) | 1EA |
| WY-NIBSC-06/128 | Monoclonal Antibody for Serotyping Bordetella pertussis Fimbrial Antigen 3 (1st International Standard) | 1EA |
| WY-NIBSC-06/140 | Pertussis Antiserum(human)1st IS-WHO international Standard | 1EA |
| WY-NIBSC-06/142 | Pertussis Antiserum (Human) 1st WHO Reference Reagent | 1EA |
| WY-NIBSC-06/164 | Influenza Virus infectious 1 VR-142 | 1EA |
| WY-NIBSC-06/166 | Antithrombin Concentrate, Human (3rd International Standard) | 1EA |
| WY-NIBSC-06/170 | Influenza Antigen A/New Caledonia/20/99 | 1EA |
| WY-NIBSC-06/192 | Influenza anti A/turkey/Turkey/1/05 (NIBRG-23) HA serum(sheepSH465 & SH466) | 1EA |
| WY-NIBSC-06/202 | Human Papillomavirus (HPV) Type 16 DNA (1st International Standard) | 1EA |
| WY-NIBSC-06/206 | Human Papillomavirus (HPV) Type 18 DNA (1st International Standard) | 1EA |
| WY-NIBSC-06/242 | Influenza Virus Infectious NYMC X-161B (A/Wisconsin/67/2005 HGR) | 1EA |
| WY-NIBSC-0688 | SARS CoV-1 spike S1 protein | 1EA |
| WY-NIBSC-07/102 | Influenza Antigen A/Solomon Islands/3/2006 (H1N1)(IVR-145) | 1EA |
| WY-NIBSC-07/104 | Influenza anti A/Solomon Islands/3/2006 (H1N1) (IVR-145) HA Serum | 1EA |
| WY-NIBSC-07/112 | Influenza Antigen A/turkey/Turkey/1/2005 (H5N1) NIBRG-23 | 1EA |
| WY-NIBSC-07/144 | Influenza Virus infectious IVR-145 | 1EA |
| WY-NIBSC-07/146 | Influenza anti A/HongKong/1073/99 like (H9) HA Serum (sheep) | 1EA |
| WY-NIBSC-07/148 | Influenza anti A/Vietnam/1194/04 (H5N1) HA Serum | 1EA |
| WY-NIBSC-07/150 | Human Plasma Anti-Influenza H5N1 (1st International Standard) | 1EA |
| WY-NIBSC-07/164 | Anti-hepatitis B surface antigen(Anti-HBs) immunoglobulin (2nd International Standard) | 1EA |
| WY-NIBSC-07/184 | Influenza anti B/Malaysia/2506/2004-HA Serum | 1EA |
| WY-NIBSC-07/202 | Recombinant soluble transferrin receptor (rsTfR)(1st WHO Reference Reagent) | 1EA |
| WY-NIBSC-07/216 | Diphtheria Toxoid (Adsorbed) (4th International Standard) | 1EA |
| WY-NIBSC-07/222 | RhD/SRY Plasma DNA sensitivity standard (1st WHO Reference Reagent) | 1EA |
| WY-NIBSC-07/228 | Blood Coagulation Factor VIIa, Concentrate, Human, 2nd International Standard | 1EA |
| WY-NIBSC-07/270 | BCG Vaccine of Danish 1331 sub-strain (1st WHO Reference Reagent) | 1EA |
| WY-NIBSC-07/272 | BCG Vaccine of Tokyo 172 sub-strain(1st WHO Reference Reagent) | 1EA |
| WY-NIBSC-07/274 | BCG Vaccine of Russian BCG-I sub-strain(1st WHO Reference Reagent) | 1EA |
| WY-NIBSC-07/278 | Influenza anti A/mallard/Netherlands/12/2000 (H7) HA serum (NIBRG-60) (sheep SH474 AND SH475) | 1EA |
| WY-NIBSC-07/286 | Monitor sample for HBsAg 0.05IU/ml | 1EA |
| WY-NIBSC-07/288 | Hepatitis B Surface Antigen (HBsAg) British Working Standard 0.2 IU/ml | 1EA |
| WY-NIBSC-07/290 | Influenza Antigen A/Anhui/1/05 (H5N1) IBCDC-RG-6 | 1EA |
| WY-NIBSC-07/296 | Influenza Virus (A/Christchurch/1/2003, H1N1) for Nucleic Acid Amplification Techniques | 1EA |
| WY-NIBSC-07/298 | Influenza Virus (A/Wyoming/3/2003, H3N2) for Nucleic Acid Amplification Techniques | 1EA |
| WY-NIBSC-07/300 | Influenza Virus (B/Jiangsu/10/2003) for Nucleic Acid Amplification Techniques | 1EA |
| WY-NIBSC-07/306 | Anti-A and anti-B in IVIG: Positive control for haemagglutination tests (WHO Reference Reagent) | 1EA |
| WY-NIBSC-07/316 | Blood Coagulation Factor VIII and Von Willebrand Factor in Plasma (6th I.S.) | 1EA |
| WY-NIBSC-07/318 | Meningococcal Group C Polysaccharide | 1EA |
| WY-NIBSC-07/328 | Unfractionated Heparin (6th I.S.) | 1EA |
| WY-NIBSC-07/336 | Influenza Antigen A/mallard/Netherlands/12/00(H7N3) NIBRG-60 | 1EA |
| WY-NIBSC-07/338 | Influenza antiserum A/Anhui/1/05 (H5) | 1EA |
| WY-NIBSC-07/348 | Influenza Virus infectious NYMC X-171B | 1EA |
| WY-NIBSC-07/350 | Blood Coagulation Factor VIII Concentrate (8th I.S.) | 1EA |
| WY-NIBSC-07/358 | Influenza Virus infectious NIB-50 | 1EA |
| WY-NIBSC-07/362 | Influenza Virus infectious IVR-149 | 1EA |
| WY-NIBSC-07/B498 | QCRHBclgMQC1-IgM Anti-HBc Quality Control Serum: Sample1 | 1EA |
| WY-NIBSC-08/100 | Influenza Antigen A/Brisbane/59/2007 (IVR-148) (H1N1) | 1EA |
| WY-NIBSC-08/108 | Influenza Virus Infectious NIBRG-91 (H9N2) | 1EA |
| WY-NIBSC-08/126 | Influenza Anti N1 Neuraminidase Serum SH485 | 1EA |
| WY-NIBSC-08/138 | Influenza Virus Infectious B/Florida/4/2006 | 1EA |
| WY-NIBSC-08/140 | Influenza Antigen B/Florida/4/2006 | 1EA |
| WY-NIBSC-08/142 | Influenza antiserum A/Anhui/1/05 (H5) | 1EA |
| WY-NIBSC-08/154 | Influenza Virus Infectious NIBRG-12 (H5N1) | 1EA |
| WY-NIBSC-08/156 | Influenza Virus Infectious NIBRG-23 30060 VE3 (H5N1) | 1EA |
| WY-NIBSC-08/158 | Fragile X Syndrome gDNA (1st International Genetic Reference Panel) | 1EA |
| WY-NIBSC-08/160 | Haemophilia A, Intron-22 inversion, gDNA, (1st International Genetic Reference Panel) | 1EA |
| WY-NIBSC-08/178 | Parainfluenza Virus serotype 2 for Nucleic Acid Amplification Techniques | 1EA |
| WY-NIBSC-08/184 | Influenza Antigen B/Malaysia/2506/2004 | 1EA |
| WY-NIBSC-08/202 | Influenza anti A/chick/Hong Kong/G9/1997/(H9) HA serum (NIBRG-94)(H9N1) | 1EA |
| WY-NIBSC-08/204 | Thyroid Stimulating Antibody (2nd I.S.) | 1EA |
| WY-NIBSC-08/208 | Influenza Antigen A/HongKong/1073/99 (H9N2) | 1EA |
| WY-NIBSC-08/210 | Influenza anti A/Cambodia/R0405050/2007 (H5) HA serum (NIBRG-86) | 1EA |
| WY-NIBSC-08/216 | Influenza Antigen A/Cambodia/RO405050/2007 (H5N1) | 1EA |
| WY-NIBSC-08/218 | Tetanus Toxoid Adsorbed (4th International Standard) | 1EA |
| WY-NIBSC-08/228 | Influenza Antigen A/chick/Hong Kong/G9/1997 (H9N2) NIBRG-91 | 1EA |
| WY-NIBSC-08/230 | Streptodornase (2nd International Standard) | 1EA |
| WY-NIBSC-08/246 | Influenza anti A/Brisbane/10/2007- like HA serum | 1EA |
| WY-NIBSC-08/248 | Influenza Virus Infectious NIBRG-107 VE2 30480 | 1EA |
| WY-NIBSC-08/252 | Influenza Virus Infectious NIBRG-109 VE2 30490 | 1EA |
| WY-NIBSC-08/256 | C1- Inhibitor, Concentrate (1st International Standard) | 1EA |
| WY-NIBSC-08/258 | Antithrombin, Plasma (3rd International Standard) | 1EA |
| WY-NIBSC-08/262 | C1 Inhibitor (Plasma)(1st International Standard) | 1EA |
| WY-NIBSC-08/266 | Sex Hormone Binding Globulin.(2nd International Standard) | 1EA |
| WY-NIBSC-08/268 | Influenza Antigen A/mallard/England/727/2006 (H2N3)NIBRG-107 | 1EA |
| WY-NIBSC-08/278 | Influenza Antigen A/Brisbane/10/2007-like (Prepared from A/Uruguay/716/2007 (NYMC X-175C)) | 1EA |
| WY-NIBSC-08/298 | Influenza Virus Infectious B/Brisbane/33/2008 30720 E5 | 1EA |
| WY-NIBSC-08/300 | Influenza Virus Infectious IVR-148 | 1EA |
| WY-NIBSC-08/304 | Influenza virus infectious NYMC X-175C | 1EA |
| WY-NIBSC-08/322 | Human Parechovirus Working Reagent for Nucleic Acid Amplification Testing | 1EA |
| WY-NIBSC-08/324 | Human Rhinovirus Genogroup A Working Reagent for Nucleic Acid Amplification Testing | 1EA |
| WY-NIBSC-08/356 | Influenza antiserum A/Japan/305/57 (H2) | 1EA |
| WY-NIBSC-08/362 | Influenza Antigen A/New York/107/2003 (H7N2)NIBRG-109 | 1EA |
| WY-NIBSC-09/100 | Influenza anti A/mallard/England/727/2006 (N3) NA serum (NIBRG-107) (Sheep SH503) | 1EA |
| WY-NIBSC-09/110 | Parvovirus B19 DNA Nucleic Acid Amplification Technology(NAT) based assays Genotype Panel(1st International Standard) | 1EA |
| WY-NIBSC-09/130 | Influenza Virus Infectious NIBRG-122 | 1EA |
| WY-NIBSC-09/136 | Granulocyte Colony Stimulating Factor (Human, rDNA Derived)(2nd International Standard) | 1EA |
| WY-NIBSC-09/138 | Genetic Reference Panel, for the quantitation of BCR-ABL translocation by RQ-PCR (1st I.S.) | 1EA |
| WY-NIBSC-09/140 | Prader Willi & Angelman Syndromes, Human gDNA,(1st International Genetic Reference Panel) | 1EA |
| WY-NIBSC-09/148 | Influenza anti A/New York/107/2003 (H7) HA serum (Sheep SH504 and SH505) | 1EA |
| WY-NIBSC-09/162 | Human Cytomegalovirus (HCMV) for Nucleic Acid Amplification Techniques (1st International Standard) | 1EA |
| WY-NIBSC-09/170 | Anti-Meningococcal factor H binding protein variant 1 (JAR4) monoclonal antibody | 1EA |
| WY-NIBSC-09/172 | Blood coagulation Factors II, VII, IX, X Plasma (4th International Standard 2010) | 1EA |
| WY-NIBSC-09/174 | Influenza Antigen A/California/7/09 (H1N1)v (NYMCX-179A)(Cell Derived) | 1EA |
| WY-NIBSC-09/182 | VWF Factor Concentrate (2nd International Standard) | 1EA |
| WY-NIBSC-09/184 | Influenza Antigen A/Vietnam/1194/2004 (H5N1) NIBRG-14 | 1EA |
| WY-NIBSC-09/186 | Chagas (anti-Trypanosoma cruzi II) antibody in human plasma(1st International Standard) | 1EA |
| WY-NIBSC-09/188 | Chagas (anti-Trypanosoma cruzi I) antibody in Human Plasma (1st International Standard) | 1EA |
| WY-NIBSC-09/196 | Influenza Antigen A/California/7/09 (H1N1)v (NIBRG-121xp) (Egg Derived) | 1EA |
| WY-NIBSC-09/222 | Human anti-Haemophilus influenzae b reference serum | 1EA |
| WY-NIBSC-09/234 | Transforming Growth Factor-BETA 3 (Human, rDNA derived TGF-? 3) (1st International Standard) | 1EA |
| WY-NIBSC-09/236 | Influenza Virus Infectious IVR-153 | 1EA |
| WY-NIBSC-09/242 | Fibrinogen Concentrate (B)(2nd International Standard) | 1EA |
| WY-NIBSC-09/260 | Epstein-Barr Virus for Nucleic Acid Amplification Techniques(1st International Standard) | 1EA |
| WY-NIBSC-09/264 | Fibrinogen Plasma (D)(3rd International Standard) | 1EA |
| WY-NIBSC-09/266 | LIAL CELL-DERIVED NEUROTROPHIC FACTOR (GDNF), human, rDNA-derived | 1EA |
| WY-NIBSC-09/268 | Influenza Virus Infectious NIBRG-121xp | 1EA |
| WY-NIBSC-09/272 | Placental growth factor Ala 21 - Arg 149, human, rDNA-derived (PlGF, PlGF-1) | 1EA |
| WY-NIBSC-09/274 | Influenza Virus Infectious NYMC X-185 | 1EA |
| WY-NIBSC-09/280 | Influenza Virus Infectious NIB-64 | 1EA |
| WY-NIBSC-09/284 | Anti-Human Neutrophil Antibody 1a WHO Reference Reagent | 1EA |
| WY-NIBSC-09/296 | Pro-Insulin, human (1st International Standard) | 1EA |
| WY-NIBSC-09/304 | Influenza Virus Infectious IVR-155 | 1EA |
| WY-NIBSC-09/308 | Influenza Serology Antigen Reagent X-179A (H1N1pdm) for HI Assay | 1EA |
| WY-NIBSC-09/310 | Influenza Antigen A/Wisconsin/15/09 (H3N2) (NYMCX-183) | 1EA |
| WY-NIBSC-10/104 | Reteplase Reference Material | 1EA |
| WY-NIBSC-10/120 | Influenza Anti A/Brisbane/59/2007 (IVR 148)(H1N1) HA serum | 1EA |
| WY-NIBSC-10/128 | Diphtheria Polyclonal Antibody | 1EA |
| WY-NIBSC-10/130 | Diphtheria Monoclonal Antibody | 1EA |
| WY-NIBSC-10/132 | Tetanus Polyclonal Antibody | 1EA |
| WY-NIBSC-10/134 | Tetanus Monoclonal Antibody | 1EA |
| WY-NIBSC-10/140 | Anti-human papillomavirus[HPV] 18 serum (1st International Standard) | 1EA |
| WY-NIBSC-10/164 | Oral Poliovaccine Sabin Type 1 reference strain [LS-c, 2ab strain] | 1EA |
| WY-NIBSC-10/168 | Oral Poliovaccine Sabin Type 3 reference | 1EA |
| WY-NIBSC-10/176 | Interleukin-29 (Interferon Lambda, Human, rDNA derived) WHO Reference Reagent | 1EA |
| WY-NIBSC-10/178 | Endotoxin (3rd International Standard) | 1EA |
| WY-NIBSC-10/198 | Anti-malaria (Plasmodium falciparum) human serum(1st WHO Reference Reagent) | 1EA |
| WY-NIBSC-10/202 | Influenza antibody (Human) to A/California/7/2009 'like' (H1N1v) virus (2nd International Standard) | 1EA |
| WY-NIBSC-10/214 | Influenza Anti N2 Neuraminidase Serum SH395 & SH396 | 1EA |
| WY-NIBSC-10/218 | Influenza Anti A/California/7/2009 (N1) NA Serum | 1EA |
| WY-NIBSC-10/226 | Influenza Virus Infectious IVR-158 | 1EA |
| WY-NIBSC-10/232 | Blood Group Genotyping Reference Reagent RBC1 (OR1R2)(WHO Reference Reagent) | 1EA |
| WY-NIBSC-10/234 | Blood Group Genotyping Reference Reagent RBC12 (ODpsi)(WHO Reference Reagent) | 1EA |
| WY-NIBSC-10/236 | Blood Group Genotyping Reference Reagent RBC4 (AR1R1)(WHO Reference Reagent) | 1EA |
| WY-NIBSC-10/238 | Blood Group Genotyping Reference Reagent RBC5 (Brr)(WHO Reference Reagent) | 1EA |
| WY-NIBSC-10/242 | Toxoplasma gondii DNA Nucleic Acid Amplification Techniques(1st International Standard) | 1EA |
| WY-NIBSC-10/252 | Factor VII Concentrate (2nd International Standard) | 1EA |
| WY-NIBSC-10/258 | Influenza Antigen A/California/7/2009-like(NIB-74) | 1EA |
| WY-NIBSC-10/262 | Diphtheria Antitoxin Human IgG(1st International Standard) | 1EA |
| WY-NIBSC-10/272 | BCG vaccine of Moreau-RJ sub-strain(1st WHO Reference Reagent) | 1EA |
| WY-NIBSC-10/286 | Follicle Stimulating Hormone, Luteinizing Hormone human, urinary for bioassay(5th International Standard) | 1EA |
| WY-NIBSC-100976 | pCAGGS-SARS-CoV-2-Spike | 1EA |
| WY-NIBSC-100980 | SARS-CoV-2 infectious virus (BetaCoV/Australia/VIC01/2020 | 1EA |
| WY-NIBSC-100985 | pCAGGS_SARS-CoV-2_Spike D614G | 1EA |
| WY-NIBSC-100986 | pCAGGS-SARS-CoV-2-Spike Bristol Deletion | 1EA |
| WY-NIBSC-100987 | Inactivated SARS-CoV-2 (BetaCoV/Australia/VIC01/2020 | 1EA |
| WY-NIBSC-100988 | Nucleic acid extracts from inactivated SARS-CoV-2 (BetaCoV/Australia/VIC01/2020 | 1EA |
| WY-NIBSC-100989 | pCRII-SARS-CoV-2 (5'UTR-NSP2) | 1EA |
| WY-NIBSC-100991 | pCRII-SARS-CoV-2 (NSP4-NSP8) | 1EA |
| WY-NIBSC-100992 | pCRII-SARS-CoV-2 (NSP4-NSP8) | 1EA |
| WY-NIBSC-100994 | pCRII-SARS-CoV-2 (NSP15-NSP16) | 1EA |
| WY-NIBSC-100996 | pCRII-SARS-CoV-2 (ORF3a-ORF6) | 1EA |
| WY-NIBSC-100998 | SARS-CoV-2 infectious virus (CVR-GLA 1) | 1EA |
| WY-NIBSC-100999 | SARS-CoV-2 infectious virus(CVR-GLA 2) | 1EA |
| WY-NIBSC-101000 | SARS-CoV-2 infectious virus(CVR-GLA 3) | 1EA |
| WY-NIBSC-101001 | VeroE6-ACE2 | 1EA |
| WY-NIBSC-101003 | VeroE6-ACE2-TMPRSS2 | 1EA |
| WY-NIBSC-101004 | A549-ACE2-TMPRSS2 | 1EA |
| WY-NIBSC-101005 | A549-ACE2 Clone8 | 1EA |
| WY-NIBSC-101006 | A549-ACE-2 Clone 8-TMPRSS2 | 1EA |
| WY-NIBSC-101007 | SARS-CoV-2 Trimeric Spike 50ug (1mg/ml in PBS) Sterile #28.05.2020 | 1EA |
| WY-NIBSC-101008 | HEK293T-ACE2-TMPRSS2 | 1EA |
| WY-NIBSC-101009 | Anti-SARS-CoV-2 Nucleocaspid protein (CR3009) | 1EA |
| WY-NIBSC-101010 | Anti-SARS-CoV-2 Nucleocapsid protein (CR3018) | 1EA |
| WY-NIBSC-101011 | Anti-SARS-CoV-2 Nucleocapsid protein (CR3009 Human/Mouse HC) | 1EA |
| WY-NIBSC-101019 | VOC-202012/01 (B.1.1.7 lineage) lot 26012021 | 1EA |
| WY-NIBSC-101022 | SARS-CoV-2 VOC202012/02 (B.1.351 lineage) passage 4 | 1EA |
| WY-NIBSC-101023 | pl.18SARS-CoV-2-Spike (B.1.1.7) 1ug (100ng/ul) lot #24032021 | 1EA |
| WY-NIBSC-101024 | pl. 18SARS-CoV-2-Spike (B.1.351) 1ug (100ng/ul) lot #24032021 | 1EA |
| WY-NIBSC-101025 | 4% formaldehyde inactivated SARS CoV-2 BetaCoV/Australia/VIC01/2020 from VeroE6/TMPRSS2 | 1EA |
| WY-NIBSC-101027 | Acid/heat inactivated SARS-CoV-2 (B.1.1.7) lot 17022021 | 1EA |
| WY-NIBSC-101029 | SARS-CoV-2 Alpha (B.1.1.7) Purified RNA extracts lot 20052021 | 1EA |
| WY-NIBSC-101030 | SARS-CoV-2 VOC-202104/02 (B.1.617.2 lineage) | 1EA |
| WY-NIBSC-101031 | SARS-CoV-2 VOC-21FEB02 (B.1.1.7 lineage + E484K) | 1EA |
| WY-NIBSC-101032 | SARS-CoV-2 Kappa (B.1.617.1 lineage | 1EA |
| WY-NIBSC-101033 | SARS-CoV-2 Delta (AY.1 sub-lineage) | 1EA |
| WY-NIBSC-101034 | SARS-CoV-2 Mu (B.1.621 lineage) | 1EA |
| WY-NIBSC-101035 | Acid/Heat Inactivated SARS-CoV-2 Beta (B.1.351 lineage) | 1EA |
| WY-NIBSC-101036 | Acid/Heat Inactivated SARS-CoV-2 Delta (B.1.617.2 lineage | 1EA |
| WY-NIBSC-101038 | 0.01% Formaldehyde Inactivated SARS-CoV-2 Beta (B.1.351 lineage) | 1EA |
| WY-NIBSC-101039 | 0.01% Formaldehyde Inactivated SARS-CoV-2 Delta (B.1.617.2 lineage) | 1EA |
| WY-NIBSC-101042 | SARS-CoV-2 Nucleocapsid protein (His tagged) | 1EA |
| WY-NIBSC-101043 | SARS-CoV-2 Nucleocapsid protein 203/204:RG>KR (His tagged) | 1EA |
| WY-NIBSC-101047 | Inactivated (Acetic Acid + Heat)SARS-CoV-2 Omicron (BA.1 sublineage) | 1EA |
| WY-NIBSC-101054 | SARS-CoV-2 Omicron BA.1.1 sublineage lot 28032022 | 1EA |
| WY-NIBSC-101055 | SARS-CoV-2 Omicron (BA.2) | 1EA |
| WY-NIBSC-101062 | HEK293T-ACE2-30F-PLP2 | 1EA |
| WY-NIBSC-1050 | IPV ELISA MAbs Type 1, 2 and 3 (Type 2; No: 1050) | 1EA |
| WY-NIBSC-11/108 | Influenza Virus infectious NYMC X-187 | 1EA |
| WY-NIBSC-11/126 | Factors II and X Concentrate (4th International standard) | 1EA |
| WY-NIBSC-11/134 | Influenza Antigen A/California/7/2009 (H1N1) Like (A/Brisbane/10/2010- cell derived) | 1EA |
| WY-NIBSC-11/170 | Erythropoietin, recombinant, for Bioassay (3rd International Standard) | 1EA |
| WY-NIBSC-11/176 | (3rd International Standard) Low Molecular Weight Heparin | 1EA |
| WY-NIBSC-11/184 | High Molecular Weight Urokinase(2nd International Standard) | 1EA |
| WY-NIBSC-11/206 | Influenza anti-A/Perth/16/2009 HA Serum | 1EA |
| WY-NIBSC-11/210 | Anti-human CD4 FITC conjugated 0.5ml | 1EA |
| WY-NIBSC-11/214 | Blood Group Genotyping Reference Reagents Panel (WHO Reference Reagent) | 1EA |
| WY-NIBSC-11/216 | Chagas Antibody Reference Panel ( 1st International Standard) | 1EA |
| WY-NIBSC-11/222 | Influenza Virus Infectious NIB-79 | 1EA |
| WY-NIBSC-11/232 | Influenza Virus Infectious B/Texas/6/2011 | 1EA |
| WY-NIBSC-11/234 | Immunoglobulin E(IgE) human serum (3rd International Standard) | 1EA |
| WY-NIBSC-11/242 | Viral Multiplex Reference | 1EA |
| WY-NIBSC-11/244 | Influenza Virus Infectious NYMC BX-49 | 1EA |
| WY-NIBSC-11/B608 | QCRHIV1QC1-Anti-HIV1:Quality Control Serum: Sample1 | 1EA |
| WY-NIBSC-12/100 | Influenza Virus Infectious NYMC X-217 | 1EA |
| WY-NIBSC-12/104 | International Standard for IPV 12/104 (3rd International Standard) | 1EA |
| WY-NIBSC-12/106 | Influenza Antigen B/Hubei-Wujiagang/158/2009 (NYMCBX-39) | 1EA |
| WY-NIBSC-12/110 | Influenza Antigen B/Wisconsin/1/2010 (cell derived) | 1EA |
| WY-NIBSC-12/112 | Influenza Antigen A/Victoria/210/2009 (H3N2) (NYMCX-187) | 1EA |
| WY-NIBSC-12/114 | Influenza Antigen A/Victoria/361/2011 (H3N2) (IVR-165) | 1EA |
| WY-NIBSC-12/116 | Influenza anti-A/Victoria/361/2011-like HA serum | 1EA |
| WY-NIBSC-12/118 | Influenza anti-B/Wisconsin/1/2010-like HA serum | 1EA |
| WY-NIBSC-12/122 | Influenza virus infectious A/turkey/Italy/3889/1999 (H7N1) | 1EA |
| WY-NIBSC-12/154 | Tumour Necrosis Factor alpha (human rDNA derived)(3rd International Standard) | 1EA |
| WY-NIBSC-12/176 | Methylated Human Serum Albumin (mHSA) | 1EA |
| WY-NIBSC-12/188 | Pegylated Granulocyte Colony Stimulating Factor (Human, rDNA derived) (1st International Standard) | 1EA |
| WY-NIBSC-12/198 | Influenza virus infectious B/Wisconsin/1/2010 34490 E5 | 1EA |
| WY-NIBSC-12/202 | Influenza virus infectious NYMC BX-39 | 1EA |
| WY-NIBSC-12/204 | Influenza Virus infectious IVR-165 | 1EA |
| WY-NIBSC-12/208 | Parvovirus B19 (3rd International Standard) | 1EA |
| WY-NIBSC-12/224 | HIV-1 NAT subtypes (Main)(2nd International Reference Panel Preparation) | 1EA |
| WY-NIBSC-12/226 | HBsAg (HBV genotype B4, HBsAg subtypes ayw1/adw2)(3rd International Standard) | 1EA |
| WY-NIBSC-12/244 | Vi polysaccharide of C freundii WHO 1st International Standard | 1EA |
| WY-NIBSC-12/250 | Influenza anti A/Mallard/England 727/2006 (H2) HA Serum | 1EA |
| WY-NIBSC-12/252 | ADAMTS 13 Plasma (1st International Standard) | 1EA |
| WY-NIBSC-12/282 | Diphtheria Toxin 1Lf/ml | 1EA |
| WY-NIBSC-12/284 | Anti-meningococcal serogroup Y monoclonal antibody | 1EA |
| WY-NIBSC-12/290 | Influenza Virus Infectious B/Brisbane/36/2012 | 1EA |
| WY-NIBSC-12/294 | Influenza Virus Infectious NYMC BX-51C | 1EA |
| WY-NIBSC-12/B612 | QCRRUBIgMQC1-Anti-Rubella IgM Quality Control Serum: Sample 1 | 1EA |
| WY-NIBSC-13/100 | Activated Blood Coagulation Factor XI (FXIa), Human (1st International Standard) | 1EA |
| WY-NIBSC-13/106 | Influenza Antigen B/Massachusetts/02/2012 | 1EA |
| WY-NIBSC-13/108 | Anti-Meningococcal serogroup B monoclonal antibody | 1EA |
| WY-NIBSC-13/112 | Influenza Antigen A/Texas/50/2012 (NYMC X-223) | 1EA |
| WY-NIBSC-13/116 | Influenza Antigen A/Texas/50/2012 (NYMC X-223A) | 1EA |
| WY-NIBSC-13/122 | Erythropoietin Antibody Reference Panel Negative Control Antibody (1st WHO Reference Panel) | 1EA |
| WY-NIBSC-13/126 | Influenza anti-B/Brisbane/60/2008-like HA serum | 1EA |
| WY-NIBSC-13/128 | Influenza Virus Infectious NIBRG-269 | 1EA |
| WY-NIBSC-13/132 | Antibodies, Human, to Toxoplasma gondii (4th International Standard) | 1EA |
| WY-NIBSC-13/134 | Influenza Antigen B/Massachusetts/02/2012 (Egg derived) | 1EA |
| WY-NIBSC-13/146 | C-Peptide, Human (1st International Standard) | 1EA |
| WY-NIBSC-13/148 | IVIG + anti-D for use with negative control IVIG | 1EA |
| WY-NIBSC-13/152 | Influenza Antigen B/Massachusetts/02/2012 (Cell Derived) | 1EA |
| WY-NIBSC-13/162 | Influenza Antigen A/Texas/50/2012 (NYMC X-223A) (Cell derived) | 1EA |
| WY-NIBSC-13/164 | Influenza Antigen A/California/7/2009 (H1N1pdm)(NYMC X-179A) | 1EA |
| WY-NIBSC-13/166 | Influenza anti-A/Anhui/1/2013 (N9) NA Serum | 1EA |
| WY-NIBSC-13/172 | Lupus Anticoagulant (1st International Reference Panel) | 1EA |
| WY-NIBSC-13/176 | Influenza Virus Infectious NIBRG-88 | 1EA |
| WY-NIBSC-13/178 | Influenza Anti-A/Texas/50/2012-like HA Serum | 1EA |
| WY-NIBSC-13/182 | Influenza Anti-B/Massachusetts/02/2012-like HA Serum | 1EA |
| WY-NIBSC-13/200 | Influenza Virus Infectious NIB-74 | 1EA |
| WY-NIBSC-13/202 | Influenza Virus Infectious NIB-74xp | 1EA |
| WY-NIBSC-13/204 | TNF Rec II- FC Fusion protein (1st International Standard) | 1EA |
| WY-NIBSC-13/206 | Plasmin (4th International Standard) | 1EA |
| WY-NIBSC-13/212 | Diphtheria Toxoid for use in Flocculation Test (3rd International Standard) | 1EA |
| WY-NIBSC-13/214 | HIV-1 Circulating Recombinant Forms RNA (1st International Reference Panel) | 1EA |
| WY-NIBSC-13/216 | Anti-meningococcal factor H binding protein variant 1 (JAR5) monoclonal | 1EA |
| WY-NIBSC-13/218 | Polio Anti Sabin type 1 (inactivated) Serum | 1EA |
| WY-NIBSC-13/220 | Polio Anti Sabin type 2 (inactivated) serum | 1EA |
| WY-NIBSC-13/222 | Polio Anti Sabin type 3 (inactivated) serum | 1EA |
| WY-NIBSC-13/224 | Influenza virus Infectious NIB-85. 36210 E5 | 1EA |
| WY-NIBSC-13/228 | Influenza Virus Infectious. A/Almaty/2958/2013. 35790 E4 | 1EA |
| WY-NIBSC-13/234 | Influenza antigen B/Brisbane/60/08 | 1EA |
| WY-NIBSC-13/238 | Anti-EV71 serum LOW (WHO Reference Reagent) | 1EA |
| WY-NIBSC-13/240 | Tetanus Immunoglobulin, Human (2nd WHO International Standard) | 1EA |
| WY-NIBSC-13/242 | FEIBA Concentrate 2nd NIBSC Working Reference Standard | 1EA |
| WY-NIBSC-13/246 | Meningococcal serogroup A polysaccharide (1st WHO International Standard) | 1EA |
| WY-NIBSC-13/248 | Influenza virus infectious NIBRG-267 (H7N9) | 1EA |
| WY-NIBSC-13/250 | Influenza Virus Infectious NIBRG-268 (H7N9) | 1EA |
| WY-NIBSC-13/252 | Influenza virus infectious NYMC X-223A | 1EA |
| WY-NIBSC-13/258 | Influenza virus infectious NYMC X-233A | 1EA |
| WY-NIBSC-13/262 | Meningococcal serogroup A polysaccharide | 1EA |
| WY-NIBSC-13/264 | Influenza Virus Infectious NYMC X-223 | 1EA |
| WY-NIBSC-13/B627 | QCRMALQC1-Anti-Malaria Quality Control Serum: Sample1 | 1EA |
| WY-NIBSC-13/B629 | QCRHBeQC1 Anti-HBe Control Serum: sample1 | 1EA |
| WY-NIBSC-13/B634 | QCRHAVIgMQC2 IgM Anti-HAV Quality Control Serum: Sample2 | 1EA |
| WY-NIBSC-13/B640 | QCRHIV1QC5 - Anti-HIV-1 Quality Control Reagent Sample 5 | 1EA |
| WY-NIBSC-13/B642 | QCRHSV2QC1-Anti-HSV2 Quality Control Serum: Sample 1 | 1EA |
| WY-NIBSC-13/B644 | QCRHIV1QC3-Anti-HIV1:Quality Control Serum:Sample 3 | 1EA |
| WY-NIBSC-14/100 | Human Papillomavirus (HPV) 11 DNA (1st International Standard) | 1EA |
| WY-NIBSC-14/104 | Human Papillomavirus (HPV) Type 45 DNA (1st International Standard) | 1EA |
| WY-NIBSC-14/106 | Influenza virus infectious. NYMC BX-51B | 1EA |
| WY-NIBSC-14/114 | JC Virus (JCV) DNA (1st International Standard) | 1EA |
| WY-NIBSC-14/116 | Influenza virus infectious NYMC X-179A | 1EA |
| WY-NIBSC-14/118 | Influenza virus infectious B/Massachusetts/2/2012 | 1EA |
| WY-NIBSC-14/140 | 1st International Standard for Anti EV71 Serum Human | 1EA |
| WY-NIBSC-14/144 | Influenza anti-N2 Neuraminidase serum (A/Victoria/361/2011) | 1EA |
| WY-NIBSC-14/146 | Influenza Antigen B/Brisbane/60/2008 (NYMCBX-35)(Cell Derived) | 1EA |
| WY-NIBSC-14/148 | Human Blood Factor IX Concentrate (5th International Standard) | 1EA |
| WY-NIBSC-14/156 | Meningococcal group X polysaccharide (1st WHO International Standard) | 1EA |
| WY-NIBSC-14/160 | High titre anti-A in IVIG working reference reagent | 1EA |
| WY-NIBSC-14/174 | Botulinum Type A Antitoxin, Equine | 1EA |
| WY-NIBSC-14/200 | Influenza Antigen A/Puerto Rico/8/34 (HINI) | 1EA |
| WY-NIBSC-14/206 | Influenza virus infectious NYMC X-247 | 1EA |
| WY-NIBSC-14/210 | Biological activities of Rituximab WHO 1st International Standard | 1EA |
| WY-NIBSC-14/212 | BK Virus (BKV)(1st International Standard) | 1EA |
| WY-NIBSC-14/224 | Influenza virus infectious. A/Switzerland/9715293/2013 | 1EA |
| WY-NIBSC-14/226 | Influenza Virus Infectious A/South Australia/55/2014 | 1EA |
| WY-NIBSC-14/228 | Influenza Virus Infectious A/Stockholm/6/2014 | 1EA |
| WY-NIBSC-14/230 | Influenza Virus Infectious. A/Norway/466/2014 | 1EA |
| WY-NIBSC-14/232 | Influenza Virus Infectious IVR-175 | 1EA |
| WY-NIBSC-14/238 | Recombinant Tissue factor | 1EA |
| WY-NIBSC-14/254 | Influenza Antigen A/Switzerland/9715293/2013 (NIB88) | 1EA |
| WY-NIBSC-14/256 | Human Papillomavirus (HPV) Type 6 DNA (1st International Standard) | 1EA |
| WY-NIBSC-14/258 | Human Papillomavirus (HPV) Type 31 DNA (1st International Standard) | 1EA |
| WY-NIBSC-14/260 | Human Papillomavirus (HPV) Type 33 DNA (1st International Standard) | 1EA |
| WY-NIBSC-14/262 | Human Papillomavirus (HPV) Type 52 DNA (1st International Standard) | 1EA |
| WY-NIBSC-14/264 | Human Papillomavirus (HPV) Type 58 DNA (1st International Standard) | 1EA |
| WY-NIBSC-14/274 | Influenza Antigen B/Brisbane/9/2014 (Egg Derived) | 1EA |
| WY-NIBSC-14/300 | High titre anti-A and anti-B in serum (WHO Reference Reagent) | 1EA |
| WY-NIBSC-14/306 | Influenza Virus Infectious NYMC X-243 40180 E13 | 1EA |
| WY-NIBSC-14/308 | Influenza Virus Infectious IVR-178 40200 E7 | 1EA |
| WY-NIBSC-14/314 | Influenza Virus Infectious NIB-88 | 1EA |
| WY-NIBSC-14/316 | Factor IX activated (FIXa) 2nd WHO International Standard | 1EA |
| WY-NIBSC-14/318 | Influenza Anti NIBRG-301 (H5) HA Serum (Sheep SH624 and SH625) | 1EA |
| WY-NIBSC-14/322 | Influenza Virus Infectious NIB-91 | 1EA |
| WY-NIBSC-14/B651 | QCRTHBcQC2-Total Anti-HBc Quality Control Serum: Sample2 | 1EA |
| WY-NIBSC-14/B653 | QCRHIV2QC3- Anti HIV2: Quality Control Serum: Sample 3 | 1EA |
| WY-NIBSC-14/B654 | QCRRUBQC1-Anti-Rubella Quality Control Serum: Sample 1 | 1EA |
| WY-NIBSC-14/B655 | QCRVZVQC1-Anti VZV: Quality Control Serum: Sample 1 | 1EA |
| WY-NIBSC-15/100 | Influenza Antigen B/Utah/9/2014 (Cell Derived) | 1EA |
| WY-NIBSC-15/102 | Activated Blood Coagulation Factor X (FXa), Human | 1EA |
| WY-NIBSC-15/104 | Influenza Antigen A/South Australia/55/2014 Cell derived | 1EA |
| WY-NIBSC-15/106 | Ancrod | 1EA |
| WY-NIBSC-15/126 | Bordetella pertussis toxin (20μg). (2nd International Standard) | 1EA |
| WY-NIBSC-15/130 | Clinical Virology Multiplex I: Immunodeficiency panel working reagent for Nucleic Acid Amplification Tests (NAT) | 1EA |
| WY-NIBSC-15/134 | Influenza Anti-A Switzerland/9715293/2013-Like HA serum | 1EA |
| WY-NIBSC-15/136 | EBOV RNA NP-VP35-GP in-run control | 1EA |
| WY-NIBSC-15/138 | EBOV RNA VP40-L in-run control | 1EA |
| WY-NIBSC-15/140 | Batroxobin | 1EA |
| WY-NIBSC-15/148 | Influenza Virus Infectious NIB-92 | 1EA |
| WY-NIBSC-15/154 | Influenza Virus Infectious NIB-93 | 1EA |
| WY-NIBSC-15/158 | Influenza Virus Infectious NYMC X-263 | 1EA |
| WY-NIBSC-15/160 | Influenza Virus Infectious NIBRG-306 | 1EA |
| WY-NIBSC-15/174 | Lupus (oligo-specific) anti-dsDNA antibodies WHO Reference Reagent | 1EA |
| WY-NIBSC-15/180 | Blood Coagulation Factor XI, 2016 Plasma Human (2nd International Standard). Blood Coagulation Factor XII, 2017 Plasma, Human (1st International Standard) | 1EA |
| WY-NIBSC-15/182 | 7th British Working Standard for Blood Coagulation Factors II, IX, X Concentrate | 1EA |
| WY-NIBSC-15/184 | Influenza Virus Infectious NYMC X-263B | 1EA |
| WY-NIBSC-15/188 | Influenza Virus Infectious NYMC X-263A | 1EA |
| WY-NIBSC-15/194 | Influenza Virus Infectious NYMC X-257A | 1EA |
| WY-NIBSC-15/196 | Influenza Virus Infectious NYMC X-261 | 1EA |
| WY-NIBSC-15/212 | Influenza Virus Infectious NYMC BX-53C | 1EA |
| WY-NIBSC-15/220 | Anti-EBOV plasma, human (WHO Reference Reagent) | 1EA |
| WY-NIBSC-15/222 | EBOV RNA NP-VP35-GP (WHO Reference Reagent) | 1EA |
| WY-NIBSC-15/224 | EBOV RNA VP40-L (WHO Reference Reagent) | 1EA |
| WY-NIBSC-15/234 | Influenza Virus Infectious B/Texas/2/2013 41340 E7 | 1EA |
| WY-NIBSC-15/238 | Influenza Antigen A/New Caledonia/71/2014 (NYMCX-257A)(Egg derived antigen) | 1EA |
| WY-NIBSC-15/240 | Erythropoietin Antibody Reference Panel A (1st WHO Reference Panel) | 1EA |
| WY-NIBSC-15/242 | Erythropoietin Antibody Reference Panel B (1st WHO Reference Panel) | 1EA |
| WY-NIBSC-15/248 | Influenza Anti A/Anhui/1/2013 (H7) HA Serum (Sheep SH644 & SH645) | 1EA |
| WY-NIBSC-15/250 | Influenza Virus Infectious NYMC BX-31 | 1EA |
| WY-NIBSC-15/252 | Influenza Virus Infectious A/California/7/2009 | 1EA |
| WY-NIBSC-15/262 | 1st International Standard for Ebola virus (EBOV) antibodies Sierra Leone Convalescent Plasma Pool | 1EA |
| WY-NIBSC-15/266 | HHV-6 Virus 1st WHO International Standard | 1EA |
| WY-NIBSC-15/270 | 1st WHO International Reference Reagent CD4 T-cells (human) | 1EA |
| WY-NIBSC-15/272 | ICS Positive Control-Lymphocytes | 1EA |
| WY-NIBSC-15/276 | Hepatitis A Virus VL For Nucleic Acid Amplification Techniques (3rd International Standard) | 1EA |
| WY-NIBSC-15/294 | Influenza virus infectious NYMC BX-59B | 1EA |
| WY-NIBSC-15/296 | Sabin monovalent Polio vaccine type 2 (1st International Standard) | 1EA |
| WY-NIBSC-15/300 | Influenza Virus Infectious NYMC BX-35 41950 E11 | 1EA |
| WY-NIBSC-15/304 | Parathyroid hormone 1-34, recombinant, human, 2nd WHO International Standard | 1EA |
| WY-NIBSC-15/B658 | QCRLYMEQC1 - Anti-Lyme QC1 | 1EA |
| WY-NIBSC-15/B664 | QCRMUMPSQC1 - Anti-Mumps Quality Control Reagent Sample 1 | 1EA |
| WY-NIBSC-15/B667 | QCRMEASQC1 Anti-Measles QC1 | 1EA |
| WY-NIBSC-15/B671 | QCRHIV1P24QC1-HIV1 p24 Antigen: Quality Control Serum: Sample1 | 1EA |
| WY-NIBSC-15/B678 | QCRPARVB19QC1 Anti-Parvovirus B19QC1 | 1EA |
| WY-NIBSC-16/104 | Norovirus GII Working reagent for Nucleic Acid Amplification Techniques | 1EA |
| WY-NIBSC-16/106 | Influenza antigen A/California/7/09 (H1N1) (NYMC-X181) | 1EA |
| WY-NIBSC-16/108 | Influenza Virus Infectious A/PR/8/34 | 1EA |
| WY-NIBSC-16/110 | Zika Virus Working Reagent for Nucleic Acid Amplification Testing (NAT) | 1EA |
| WY-NIBSC-16/114 | Influenza anti - A/California/7/09 HA serum | 1EA |
| WY-NIBSC-16/118 | Influenza Antigen B/Brisbane/60/2008 (NYMC BX-35) (Egg Derived) | 1EA |
| WY-NIBSC-16/120 | WHO 1st International Reference Panel for Genomic JAK2 V617F | 1EA |
| WY-NIBSC-16/126 | Native Vi polysaccharide (S. Typhi) (1st International Standard) | 1EA |
| WY-NIBSC-16/138 | Anti-Typhoid capsular Vi polysaccharide Ig (Human) 1st WHO International Standard | 1EA |
| WY-NIBSC-16/152 | Meningococcal Serogroup W Polysaccharide | 1EA |
| WY-NIBSC-16/164 | Sabin bivalnet Polio vaccines types 1 and 3 (1st International Standard) | 1EA |
| WY-NIBSC-16/170 | Infliximab (1st International Standard) | 1EA |
| WY-NIBSC-16/182 | Influenza Anti-A/Hong Kong/4801/2014-like HA Serum | 1EA |
| WY-NIBSC-16/192 | Influenza Anti - B/Brisbane/60/2008-HA serum | 1EA |
| WY-NIBSC-16/194 | HIV-1 RNA (4th International Standard) | 1EA |
| WY-NIBSC-16/196 | Sabin monovalent Polio vaccine type 1(1st International Standard) | 1EA |
| WY-NIBSC-16/200 | Influenza Virus Infectious NIB-58 | 1EA |
| WY-NIBSC-16/202 | OPV reference mOPV 3 | 1EA |
| WY-NIBSC-16/204 | 7th WHO International Standard for Rabies Vaccine | 1EA |
| WY-NIBSC-16/206 | Meningococcal serogroup Y Polysaccharide | 1EA |
| WY-NIBSC-16/208 | Influenza Virus Infectious NIB-97 42090 E7 | 1EA |
| WY-NIBSC-16/210 | HIV-1 P24 Antigen (1st international reference panel) | 1EA |
| WY-NIBSC-16/236 | HIV-2 p26 Antigen (VLP)-HIV-2 A7312 (1st WHO Reference Reagent) | 1EA |
| WY-NIBSC-16/238 | Influenza Antigen A/Anhui/1/2013 (NIBRG-268) (H7N9) | 1EA |
| WY-NIBSC-16/242 | Influenza Virus Infectious NIB-98 42110 E7 | 1EA |
| WY-NIBSC-16/250 | 1st International Reference Panel for genomic KRAS codons 12 and 13 mutations | 1EA |
| WY-NIBSC-16/268 | Influenza Virus Infectious X-273 | 1EA |
| WY-NIBSC-16/270 | Influenza Virus Infectious IVR-180 42400 E3/D7/E1 | 1EA |
| WY-NIBSC-16/274 | Influenza Virus Infectious X-275A 42010 E13 | 1EA |
| WY-NIBSC-16/278 | Anti-D Immunglobulin control preparation | 1EA |
| WY-NIBSC-16/282 | Influenza Virus Infectious X-285 42430 ExE1 | 1EA |
| WY-NIBSC-16/286 | Influenza Antigen A/Hong Kong/4801/2014 (NYMC X-263B) | 1EA |
| WY-NIBSC-16/288 | Influenza Virus Infectious X-283A 42420 ExE1 | 1EA |
| WY-NIBSC-16/290 | Influenza Virus Infectious X-285A 42440 ExE1 | 1EA |
| WY-NIBSC-16/292 | Influenza Antigen A/Singapore/GP1908/2015 (IVR-180) | 1EA |
| WY-NIBSC-16/296 | Human Immunodeficiency Virus type 2 RNA (HIV-2) for Nucleic Acid Amplification Techniques (2nd International Standard) | 1EA |
| WY-NIBSC-16/302 | Tetanus Toxoid for use in Flocculation Test (3rd International Standard) | 1EA |
| WY-NIBSC-16/320 | Zika Antibody Working reagent | 1EA |
| WY-NIBSC-16/324 | Human Adenovirus DNA for nucleic acid amplification techniques (1st WHO international Standard) | 1EA |
| WY-NIBSC-16/332 | Anti-D Immunoglobulin (Replacement IS) | 1EA |
| WY-NIBSC-16/344 | WHO Anti-EBOV Convalescent Plasma (International Reference Panel) | 1EA |
| WY-NIBSC-16/352 | Anti-Asian Lineage Zika Virus Antibody (human) (1st international standard) | 1EA |
| WY-NIBSC-16/358 | Streptokinase (4th WHO International Standard) | 1EA |
| WY-NIBSC-16/360 | Influenza Virus Infectious NIB-96 41920 E7 | 1EA |
| WY-NIBSC-16/362 | Influenza Virus Infectious NYMC X-291 42530 E8 | 1EA |
| WY-NIBSC-16/364 | 3rd International Standard for Prekallikrein Activator | 1EA |
| WY-NIBSC-16/366 | Influenza Virus Infectious NYMC X-291A 42540 E8 | 1EA |
| WY-NIBSC-16/368 | HSV-1 | 1EA |
| WY-NIBSC-16/374 | Blood Coagulation Factor V, Plasma, Human. (WHO 2nd International Standard) | 1EA |
| WY-NIBSC-16/376 | Plasmodium falciparum antigens (1st International Standard) | 1EA |
| WY-NIBSC-16/B687 | QCRHIV1RTDQC1- Anti-HIV1 Quality Control Serum: Sample 1 for Rapid Test Devices | 1EA |
| WY-NIBSC-16/B693 | QCRCMVIgMQC1 IgM Anti-CMV QC1 | 1EA |
| WY-NIBSC-16/B697 | QCREBVVCAQC1 | 1EA |
| WY-NIBSC-16/B704 | QCRTHBcQC1-Total Anti-HBc Quality Control Serum: Sample 1 | 1EA |
| WY-NIBSC-1-7 | Fimbrae monoclonal antibody, clone 1-7 | 1EA |
| WY-NIBSC-17/100 | Prostate Specific Antigen (human)(total: PSA-ACT + free PSA) | 1EA |
| WY-NIBSC-17/102 | Prostate Specific Antigen (human) (Free), (2nd WHO International Standard) | 1EA |
| WY-NIBSC-17/106 | Influenza Anti-A/Michigan/45/2015-like HA Serum | 1EA |
| WY-NIBSC-17/122 | HSV-2 | 1EA |
| WY-NIBSC-17/124 | Influenza Virus Infectious NYMC BX-63 42790 E10/E1 | 1EA |
| WY-NIBSC-17/126 | Influenza Virus Infectious NYMC BX-63A 42780 E10/E1 | 1EA |
| WY-NIBSC-17/132 | Influenza Anti NIBRG-306 (H5) HA Serum (sheep SH672 and SH637) | 1EA |
| WY-NIBSC-17/136 | Influenza Virus Infectious NIBRG-375 (H7N9) | 1EA |
| WY-NIBSC-17/142 | Influenza Antigen A/Duck Vietnam/NCVD-1584/2012 (NIBRG-301) (H5N1) | 1EA |
| WY-NIBSC-17/154 | Influenza Antigen A/Michigan/45/2015 (NYMC X-275) | 1EA |
| WY-NIBSC-17/156 | Influenza Virus Infectious CNIC-1701 42910 E9 | 1EA |
| WY-NIBSC-17/162 | Influenza Virus Infectious NYMC X-299 42920 E10 | 1EA |
| WY-NIBSC-17/164 | Influenza Virus Infectious B/Maryland/15/2016 42800 E5 | 1EA |
| WY-NIBSC-17/182 | Influenza Antigen A/Michigan/45/2015 (NYMC X-275) | 1EA |
| WY-NIBSC-17/184 | Influenza Virus Infectious NIB-103 42610 E7 | 1EA |
| WY-NIBSC-17/190 | Influenza Virus Infectious NYMC X-297 42940 E11 | 1EA |
| WY-NIBSC-17/194 | Influenza Virus Infectious NIB-104 | 1EA |
| WY-NIBSC-17/204 | 1st International Standard for Darbepoetin | 1EA |
| WY-NIBSC-17/206 | 14th British Standard for Coagulation Factor VIII Concentrate, Human | 1EA |
| WY-NIBSC-17/210 | Influenza Virus Infectious IVR-186 43310 E8 | 1EA |
| WY-NIBSC-17/232 | Tumor Necrosis Factor alpha (human rDNA derived) | 1EA |
| WY-NIBSC-17/236 | Adalimumab (1st WHO International Standard) | 1EA |
| WY-NIBSC-17/240 | 5% Immunoglobulin (Negative Control) | 1EA |
| WY-NIBSC-17/246 | Influenza Antigen A/Singapore/INFIMH-16-0019/2016 (NIB-104) | 1EA |
| WY-NIBSC-17/252 | Influenza Virus Infectious NYMC BX-69 43220 E13 | 1EA |
| WY-NIBSC-17/256 | Influenza Virus Infectious NYMC BX-69A | 1EA |
| WY-NIBSC-17/258 | Influenza Virus Infectious B/Alabama/2/2017 | 1EA |
| WY-NIBSC-17/264 | Influenza Virus Infectious A/Michigan/45/2015 43470 E5 | 1EA |
| WY-NIBSC-17/B710 | QCRTOXOQC1 - Anti-Toxoplasma gondii Quality Control Reagent Sample 1 | 1EA |
| WY-NIBSC-17/B713 | QCRSYPHQC2-Anti-Syphilis Quality Control Serum: sample 2 | 1EA |
| WY-NIBSC-17/B717 | QCRHBsGQC1-HBsAg Quality Control Serum: Sample1 | 1EA |
| WY-NIBSC-17/B723 | QCRHEVQC1 - Anti-Hepatitis E Quality Control Sample 1 | 1EA |
| WY-NIBSC-17/B725 | QCRTHAVQC1-Total Anti-HAV Quality Control Serum: Sample1 | 1EA |
| WY-NIBSC-17/B728 | QCRHEVIgMQC1 - IgM Anti-Hepatitis E Quality Control Sample 1 | 1EA |
| WY-NIBSC-18/100 | Influenza Antigen B/Maryland/15/2016 | 1EA |
| WY-NIBSC-18/104 | Influenza Antigen B/Maryland/15/2016 (NYMC BX-69A) | 1EA |
| WY-NIBSC-18/108 | Influenza anti-A/Singapore/INFIMH-16-0019/2016- like HA serum | 1EA |
| WY-NIBSC-18/110 | Influenza Antigen A/Singapore/INFIMH-16-0019/2016 (IVR-186) | 1EA |
| WY-NIBSC-18/112 | Influenza anti-A/Guangdong-17SF003/2016 (H7) (NIBRG-375) HA Serum | 1EA |
| WY-NIBSC-18/116 | WHO International Standard Enterovirus 71 (EV71) Inactivated vaccine (Geno Group C4) | 1EA |
| WY-NIBSC-18/118 | 1st International Standard for HCT 15 Cancer Genome | 1EA |
| WY-NIBSC-18/120 | WHO Reference Reagent Enterovirus 71 (EV71) Inactivated Vaccine (Geno Group C4) | 1EA |
| WY-NIBSC-18/130 | 1st International Standard for MOLT-4 Cancer Genome | 1EA |
| WY-NIBSC-18/132D | WHO Reference Reagent Lentiviral Vector Copy number by digital PCR 6.75 log 10 LV copies/ampoule | 1EA |
| WY-NIBSC-18/132Q | WHO Reference Reagent Lentiviral Vector Copy number by quantitative PCR 6.89 log 10 LV copies/ampoule | 1EA |
| WY-NIBSC-18/134 | Influenza Virus Infectious NIBRG-301 (H5N1) | 1EA |
| WY-NIBSC-18/136 | Influenza Virus Infectious NIBRG-14 (H5N1) | 1EA |
| WY-NIBSC-18/138 | Influenza Virus Infectious NYMC X-307A | 1EA |
| WY-NIBSC-18/140 | Influenza Virus Infectious NYMC X-307 | 1EA |
| WY-NIBSC-18/144 | WHO 1st Reference Reagent for Lentiviral Vector Integration Site Analysis | 1EA |
| WY-NIBSC-18/146 | Pertussis antiserum (human) panel | 1EA |
| WY-NIBSC-18/154 | Bordetella pertussis, pertactin, PRN | 1EA |
| WY-NIBSC-18/156 | WHO Reference Reagent Enterovirus 71 (EV71) Inactivated Vaccine (Geno Group B4) | 1EA |
| WY-NIBSC-18/160 | Influenza Virus Infectious NYMC X-311 | 1EA |
| WY-NIBSC-18/164 | 1st International Standard for ATDB102 Genome | 1EA |
| WY-NIBSC-18/166 | Influenza Virus Infectious NIB-112 43990 E6 | 1EA |
| WY-NIBSC-18/168 | Influenza Virus Infectious A/Switzerland/8060/2017 | 1EA |
| WY-NIBSC-18/170 | Influenza anti-B/Colorado/06/2017-like HA serum | 1EA |
| WY-NIBSC-18/174 | Influenza Virus Infectious A/Brisbane/1/2018 | 1EA |
| WY-NIBSC-18/180 | 2nd International Standard for Diphtheria Antitoxin Equine | 1EA |
| WY-NIBSC-18/184 | Hepatitis C virus RNA for nucleic acid amplification techniques (6th WHO International Standard) | 1EA |
| WY-NIBSC-18/188 | Influenza Antigen A / Switzerland / 8060 / 2017 (NIB-112) | 1EA |
| WY-NIBSC-18/190 | Influenza Antigen A / Brisbane/ 01/2018 (NYMC X-311) | 1EA |
| WY-NIBSC-18/192 | Influenza Anti-A/Switzerland/8060/2017-like (H3N2) HA Serum | 1EA |
| WY-NIBSC-18/194 | Influenza Virus Infectious NYMC X-275 (Influenza Reagent) | 1EA |
| WY-NIBSC-18/196 | Influenza Antigen A/Guangdong/17SF003/2016. NIBRG-375 (H7N9) | 1EA |
| WY-NIBSC-18/208 | WHO Reference Reagent for West Nile Virus lineage 2 RNA for NAT-based assays | 1EA |
| WY-NIBSC-18/210 | Bevacizumab (1st WHO International Standard) | 1EA |
| WY-NIBSC-18/220 | Anti-HPA 15b minimum potency reagent (WHO Reference Reagent) | 1EA |
| WY-NIBSC-18/226 | Influenza Virus Infectious IVR-190 44250 E12 | 1EA |
| WY-NIBSC-18/230 | Influenza Virus Infectious B/Colorado/06/2017 43460 E7 | 1EA |
| WY-NIBSC-18/234 | Influenza Virus Infectious NIB116-B 44230 E5 | 1EA |
| WY-NIBSC-18/236 | Influenza Virus Infectious A/Brisbane/02/2018 | 1EA |
| WY-NIBSC-18/238 | Influenza Antigen A/Brisbane/02/2018 (IVR-190) (H1N1) | 1EA |
| WY-NIBSC-18/240 | Influenza Virus Infectious NYMC X-327 44280 E17 | 1EA |
| WY-NIBSC-18/242 | Influenza Virus Infectious A/Kansas/14/2017 43880 E8 | 1EA |
| WY-NIBSC-18/244 | Human Chorionic Gonadotropin (hCG) (6th International Standard) | 1EA |
| WY-NIBSC-18/248 | Von Willebrand Factor Concentrate (WHO 3rd International Standard) | 1EA |
| WY-NIBSC-18/B732 | QCRNEGQC1-Negative Quality Control Serum: Sample1 | 1EA |
| WY-NIBSC-18/B733 | QCREBVIgMQC1 | 1EA |
| WY-NIBSC-18/B742 | QCRLYMEIgMQC1 IgM Anti-Lyme QC1 | 1EA |
| WY-NIBSC-19/102 | Influenza anti-A/Brisbane/02/2018-like (H1N1) HA Serum (Sheep 698, 699, 700, 701) | 1EA |
| WY-NIBSC-19/104 | Influenza antigen A/Kansas/14/2017 (NYMC X-327) (H3N2) | 1EA |
| WY-NIBSC-19/106 | Influenza Virus Infectious IVR-195 44300 E9 | 1EA |
| WY-NIBSC-19/108 | Trastuzumab (1st WHO international Standard) | 1EA |
| WY-NIBSC-19/112 | Influenza Virus Infectious NIB-110 | 1EA |
| WY-NIBSC-19/116 | 1st WHO Plasmodium Vivax Antigen (LDH) | 1EA |
| WY-NIBSC-19/118 | Ferritin (Human, Recombinant) | 1EA |
| WY-NIBSC-19/120 | Influenza Virus Infectious X-327 A 44310 E18 | 1EA |
| WY-NIBSC-19/146 | Influenza Virus Infectious CNIC-1903 | 1EA |
| WY-NIBSC-19/148 | Influenza Virus Infectious CNIC-1902 44320 E10 | 1EA |
| WY-NIBSC-19/152 | Influenza anti-A/Kansas/14/2017 - Like (H3N2) HA Serum | 1EA |
| WY-NIBSC-19/154 | Influenza Antigen A/Kansas/ 12/2017 (IVR-195) (H3N2) | 1EA |
| WY-NIBSC-19/156 | Panel of recombinant antibody controls for Cytokine Release Assays | 1EA |
| WY-NIBSC-19/160 | Influenza Virus Infectious A/California/7/09 44430 E6 | 1EA |
| WY-NIBSC-19/164 | VZV Nucleic acid amplification techniques (1st WHO International Standard) | 1EA |
| WY-NIBSC-19/172 | Influenza Virus Infectious BVR-11 | 1EA |
| WY-NIBSC-19/174 | Influenza Virus Infectious IVR-197 (H3N2) 44850 E14 | 1EA |
| WY-NIBSC-19/176 | Influenza Virus Infectious B/Victoria/705/2018 | 1EA |
| WY-NIBSC-19/178 | 1st WHO International Standard for Anti-MERS-CoV Immunoglobulin G (Human) | 1EA |
| WY-NIBSC-19/180 | Non WHO Reference material Working reagent for Anti-MERS-CoV Antibody | 1EA |
| WY-NIBSC-19/188 | 3rd International Standard Thrombin | 1EA |
| WY-NIBSC-19/192 | Influenza Virus Infectious IVR-202 (H3N2) 44880 E10 | 1EA |
| WY-NIBSC-19/194 | Influenza Virus Infectious B/Brisbane/35/2018 | 1EA |
| WY-NIBSC-19/204 | Influenza Antigen A/Newcastle/82/2018 (H3N2) (cell derived) | 1EA |
| WY-NIBSC-19/206 | Influenza Virus Infectious X-181 45030 E8 | 1EA |
| WY-NIBSC-19/208 | Influenza Antigen B/Victoria/705/2018 (BVR-11) (B Victoria Lineage) | 1EA |
| WY-NIBSC-19/210 | Influenza Antigen B/Darwin/7/2019 (B Victoria Lineage) (Cell Derived) | 1EA |
| WY-NIBSC-19/212 | Influenza Antigen A/South Australia/34/2019 (IVR-197) (H3N2) | 1EA |
| WY-NIBSC-19/216 | Influenza Anti-A/South Australia/34/2019-Like (H3N2) HA Serum (Sheep 712, 713, 714, 715, 716) | 1EA |
| WY-NIBSC-19/224 | Collection of WHO International Standards for Human Papillomavirus (HPV) DNA genotypes HPV16, HPV18, HPV6, HPV11 | 1EA |
| WY-NIBSC-19/226 | Collection of WHO International Standards for Human Papillomavirus (HPV) DNA genotypes HPV31, HPV33, HPV45, HPV52, HPV58 | 1EA |
| WY-NIBSC-19/228 | Influenza Virus Infectious A/South Australia/34/2019 | 1EA |
| WY-NIBSC-19/230 | Influenza Virus Infectious A/Christchurch/516/2019 H3N2 45010 E4 | 1EA |
| WY-NIBSC-19/238 | Influenza Antigen B/Washington/02/2019 (B Victoria Lineage) | 1EA |
| WY-NIBSC-19/240 | British Working Standard for Anti-HCV | 1EA |
| WY-NIBSC-19/244 | Third WHO International Standard for Anti-Rabies Immunoglobulin | 1EA |
| WY-NIBSC-19/246 | 1st International Standard for human vascular endothelial growth factor-165 (VEGF165) | 1EA |
| WY-NIBSC-19/256 | Influenza Virus Infectious BX-85C 45230 E13 | 1EA |
| WY-NIBSC-19/258 | Influenza Virus Infectious CNIC-1906 44910 E3+3/E9/E1 | 1EA |
| WY-NIBSC-19/260 | Anti-thyroid peroxidase antibodies (1st WHO International Standard) | 1EA |
| WY-NIBSC-19/276 | Influenza Virus Infectious NIB-121 (H3N2) 45180 E7/E1/E5 | 1EA |
| WY-NIBSC-19/290 | First WHO International Standard for anti-human papillomavirus type 33 serum | 1EA |
| WY-NIBSC-19/296 | First WHO International Standard for anti-human papillomavirus type 52 serum | 1EA |
| WY-NIBSC-19/298 | First WHO International Standard for anti-human papillomavirus type 6 serum | 1EA |
| WY-NIBSC-19/300 | First WHO International Standard for anti-human papillomavirus type 58 serum | 1EA |
| WY-NIBSC-19/306 | Influenza Antigen A/Victoria/2454/2019 (IVR-207) (H1N1) | 1EA |
| WY-NIBSC-19/308 | Influenza Antigen B/Singapore/INFTT-16-0610/2016 (B Yamagata lineage) (cell derived) | 1EA |
| WY-NIBSC-19/312 | Influenza Antigen A/Guangdong-Maonan/SWL1536/2019 (CNIC-1909) (H1N1) | 1EA |
| WY-NIBSC-19/314 | Influenza Anti-A/ Guangdong-Maonan/SWL 1536/2019-like (H1N1) HA Serum (Sheep 723, 724, 725, 726, 727, 728) | 1EA |
| WY-NIBSC-19/316 | Influenza anti-A/hongKong/2671/2019-like (H3N2) HA Serum (Sheep 729, 730, 731, 732, 733, 734) | 1EA |
| WY-NIBSC-19/318 | Influenza anti-B/Washington/02/2019-like (B Victoria lineage) HA Serum (Sheep 737, 738, 739, 740, 741, 742) | 1EA |
| WY-NIBSC-19/320 | Influenza anti-N2 Neuraminidase Serum (A/South Australia/34/2019) (Sheep 735, 736) | 1EA |
| WY-NIBSC-19/322 | Influenza anti-B/Phuket/3073/2013-like (B Yamagata Lineage) HA serum (Sheep 743, 744, 745, 746, 747, 748) | 1EA |
| WY-NIBSC-19/B747 | QCRHIV2QC4 - Anti HIV2 Quality Control Serum Sample 4 | 1EA |
| WY-NIBSC-19/B754 | Anti-Rubella QC2 | 1EA |
| WY-NIBSC-20/102 | Influenza Virus Infectious IVR-207 (H1N1) 45370 E4/E6/E1 | 1EA |
| WY-NIBSC-20/106 | Influenza Virus Infectious A/Victoria/2454/2019 (H1N1) 45360 E4/E1 | 1EA |
| WY-NIBSC-20/108 | Influenza Antigen A/HongKong/2671/2019 (NIB-121)(H3N2) | 1EA |
| WY-NIBSC-20/110 | SARS-CoV-2 (NAT) | 1EA |
| WY-NIBSC-20/112 | IVIG + Anti-D (13/148)x2 Negative Control IVIG (12/300) x2 | 1EA |
| WY-NIBSC-20/132 | Influenza Antigen A/HongKong/2671/2019 (IVR-208) (H3N2) | 1EA |
| WY-NIBSC-20/134 | Influenza Virus Infectious BX-57 45430 E4/E10/E1 | 1EA |
| WY-NIBSC-20/138 | Working Reagent for SARS-CoV-2 RNA | 1EA |
| WY-NIBSC-20/146 | First WHO International Standard for SARS-CoV-2 RNA | 1EA |
| WY-NIBSC-20/152 | First WHO International Standard for Mycobacterium tuberculosis (H37Rv) DNA for NAT-based assays | 1EA |
| WY-NIBSC-20/162 | NIBSC Anti-SARS-CoV-2 Antibody Diagnostic Calibrant | 1EA |
| WY-NIBSC-20/164 | Influenza Virus Infectious BX-87C (B/VIC) 45460 E3/E10/E1 | 1EA |
| WY-NIBSC-20/170 | NHS winter Multiplex Working Reagent for Nucleic acid amplification testing (NAT) | 1EA |
| WY-NIBSC-20/174 | First WHO International Standard for anti-human papillomavirus type 11 serum | 1EA |
| WY-NIBSC-20/176 | First WHO International Standard for anti-human papillomavirus type 31 serum | 1EA |
| WY-NIBSC-20/178 | First WHO International Standard for anti-human papillomavirus type 45 serum | 1EA |
| WY-NIBSC-20/180 | Influenza A (H1N1) Panel | 1EA |
| WY-NIBSC-20/182 | Influenza A (H3N2) Panel | 1EA |
| WY-NIBSC-20/184 | Influenza B Panel | 1EA |
| WY-NIBSC-20/186 | RSV A Panel | 1EA |
| WY-NIBSC-20/188 | RSV B Panel | 1EA |
| WY-NIBSC-20/190 | SARS-CoV-2 Panel | 1EA |
| WY-NIBSC-20/202 | Anti-Lassa Virus Antibodies (1st International Standard) | 1EA |
| WY-NIBSC-20/214 | Influenza Virus Infectious IVR-216 (H1N1) 45630 E4/D6/E1 | 1EA |
| WY-NIBSC-20/218 | Follicle Stimulating Hormone (3rd International Standard) | 1EA |
| WY-NIBSC-20/220 | Influenza Virus Infectious IVR-217 (H1N1) 45640 E4/D6/E1 | 1EA |
| WY-NIBSC-20/234 | Influenza Anti-A/Victoria/2570/2019-like (H1N1) HA Serum (Sheep 749, 750, 751, 752, 753, 754) | 1EA |
| WY-NIBSC-20/236 | Influenza Virus Infectious X-349 (H1N1) E3/E9/E1 45720 | 1EA |
| WY-NIBSC-20/238 | Influenza Virus Infectious X-349A (H1N1) E3/E11/E1 45730 | 1EA |
| WY-NIBSC-20/264 | Influenza Virus Infectious X-341 + 1P (H3N2) | 1EA |
| WY-NIBSC-20/292 | 2nd International Standard for Factor XIII Plasma, Human | 1EA |
| WY-NIBSC-20/294 | Influenza Virus Infectious X-347 (H3N2) | 1EA |
| WY-NIBSC-20/296 | Influenza Virus Infectious X-347A (H3N2) | 1EA |
| WY-NIBSC-20/302 | WHO International Reference Reagent for GUT Microbiome analysis by NGS (Gut-Mix RR) | 1EA |
| WY-NIBSC-20/310 | Influenza Virus Infectious A/Cambodia/E0826360/2020 (H3N2) | 1EA |
| WY-NIBSC-20/314 | 2nd WHO International Standard For Meningococcal Capsular Group C Polysaccharide | 1EA |
| WY-NIBSC-20/318 | Influenza Virus Infectious IVR-221 (H3N2) | 1EA |
| WY-NIBSC-20/322 | Influenza Virus Infectious A/Singapore/INFIMH-16-0019/2016 (H3N2) | 1EA |
| WY-NIBSC-20/B758 | QCRHIV1p24QC2-HIV1 p24 Antigen: Quality Control Serum: Sample2 | 1EA |
| WY-NIBSC-20/B760 | QCRHBsQC1 | 1EA |
| WY-NIBSC-20/B762 | QCRHIV1QC2 - Anti-HIV Quality Control Serum sample 2 | 1EA |
| WY-NIBSC-20/B764 | QCRSARSCoV2QC1 | 1EA |
| WY-NIBSC-20/B767 | QCRSYPHQC1-Anti-Syphilis Quality Control Serum: Sample 1 | 1EA |
| WY-NIBSC-20/B774 | QCRPARVB19IgMQC1 - IgM Anti-Parvovirus B19 Quality Control Reagent 1 | 1EA |
| WY-NIBSC-21/100 | Influenza Antigen A/Cambodia/e0826360/2020 (IVR-224) (H3N2) | 1EA |
| WY-NIBSC-21/110 | Working Reagent for Lassa virus RNA | 1EA |
| WY-NIBSC-21/112 | First WHO International Standard for Lassa virus RNA | 1EA |
| WY-NIBSC-21/116 | Influenza Antigen A/Tasmania/503/2020 (IVR-221) (H3N2) | 1EA |
| WY-NIBSC-21/118 | Influenza anti-A/Cambodia/e0826360/ 2020-Like (H3N2) HA Serum | 1EA |
| WY-NIBSC-21/120 | Influenza Anti-A/Victoria/2570/2019-like (H1N1) HA Serum | 1EA |
| WY-NIBSC-21/122 | Influenza Virus Infectious X-357A (H3N2) | 1EA |
| WY-NIBSC-21/124 | Influenza Virus Infectious B/HongKong/574/2019 (B-Victoria lineage) | 1EA |
| WY-NIBSC-21/130 | Influenza Virus Infectious SAN-004A (H3N2) | 1EA |
| WY-NIBSC-21/132 | Influenza Virus Infectious B/Phuket/3073/2013 (B-Yamagata lineage) | 1EA |
| WY-NIBSC-21/136 | Influenza Antigen B/Phuket/3073/2013 (B Yamagata lineage) | 1EA |
| WY-NIBSC-21/148 | Influenza Virus Infectious X-359 (H3N2) | 1EA |
| WY-NIBSC-21/150 | Influenza Virus Infectious X-359A (H3N2) | 1EA |
| WY-NIBSC-21/156 | Influenza Virus Infectious BX-93A (B-Victoria Lineage) | 1EA |
| WY-NIBSC-21/158 | Influenza Virus Infectious BX-93B (B-Victoria Lineage) | 1EA |
| WY-NIBSC-21/160 | Influenza Virus Infectious X-353 (H3N2) | 1EA |
| WY-NIBSC-21/164 | Influenza Virus Infectious X-355B (H3N2) | 1EA |
| WY-NIBSC-21/166 | Influenza Virus Infectious X-355A-CL (H3N2) | 1EA |
| WY-NIBSC-21/170 | 1st International Standard 2022 for the in vitro bioactivities of Cetuximab | 1EA |
| WY-NIBSC-21/180 | Meningococcal Capsular Group W polysaccharide | 1EA |
| WY-NIBSC-21/186 | Influenza Virus Infectious A/Tasmania/503/2020 (H3N2) | 1EA |
| WY-NIBSC-21/190 | Influenza Virus Infectious X-361A (H3N2) | 1EA |
| WY-NIBSC-21/192 | Influenza Virus Infectious BX-97A (B-Victoria Lineage) | 1EA |
| WY-NIBSC-21/194 | Influenza Virus Infectious A/Hong Kong/2671/2019 | 1EA |
| WY-NIBSC-21/196 | Influenza Virus Infectious IVR-224 (H3N2) | 1EA |
| WY-NIBSC-21/204 | Influenza Virus Infectious IVR-227 (H3N2) | 1EA |
| WY-NIBSC-21/212 | Influenza Virus Infectious A/Darwin/6/2021 (H3N2) | 1EA |
| WY-NIBSC-21/214 | Influenza Virus Infectious A/Darwin/9/2021 (H3N2) | 1EA |
| WY-NIBSC-21/216 | Influenza Virus Infectious BVR-25 (B-Victoria Lineage) | 1EA |
| WY-NIBSC-21/224 | Influenza Virus Infectious B/Austria/1359417/2021 (B/Victoria Lineage) | 1EA |
| WY-NIBSC-21/226 | Influenza Virus Infectious NIB-127 (H3N2) | 1EA |
| WY-NIBSC-21/228 | Influenza Virus Infectious NIB-126 (H3N2) | 1EA |
| WY-NIBSC-21/230 | 1st WHO Reference Reagent Tetanus Antitoxin Equine for use in Flocculation Test | 1EA |
| WY-NIBSC-21/238 | Influenza Virus Infectious A/Guangdong-Maonan/SWL/1536/2019 (H1N1) | 1EA |
| WY-NIBSC-21/240 | Influenza Virus Infectious CNIC-1909 (H1N1) | 1EA |
| WY-NIBSC-21/242 | Influenza Virus Infectious B/Singapore/WUH4618/2021 (B-Victoria Lineage) | 1EA |
| WY-NIBSC-21/244 | Influenza Virus Infectious B/Michigan/1/2021 (B/Victoria Lineage) | 1EA |
| WY-NIBSC-21/246 | Influenza Virus Infectious IVR-228 (H3N2) | 1EA |
| WY-NIBSC-21/248 | Influenza Virus Infectious BVR-27 (B-Victoria Lineage) 46580 | 1EA |
| WY-NIBSC-21/252 | Influenza Virus Infectious IVR-215 (H1N1) | 1EA |
| WY-NIBSC-21/268 | Anti-pneumococcal serotype 1 monoclonal antibody (clone13-110A | 1EA |
| WY-NIBSC-21/270 | Anti-pneumococcal serotype 3 monoclonal antibody (clone 15-103FC11 IH5) | 1EA |
| WY-NIBSC-21/272 | Anti-pneumococcal serotype 5 monoclonal antibody (clone 1366LC1 IE11) | 1EA |
| WY-NIBSC-21/274 | Anti-pneumococcal serotype 6A / 6C monoclonal antibody (clone 14-107 JG10 IA1/IB1 IIG10) | 1EA |
| WY-NIBSC-21/276 | Anti-pneumococcal serotype 7F monoclonal antibody (clone 15-102HG6 ID8) | 1EA |
| WY-NIBSC-21/278 | Anti-pneumococcal serotype 8 monoclonal antibody (clone 7D3) | 1EA |
| WY-NIBSC-21/280 | Anti-pneumococcal serotype 9N monoclonal antibody (clone 18-125BG4 ID4) | 1EA |
| WY-NIBSC-21/282 | Anti-pneumococcal serotype 9V monoclonal antibody (clone 15-112EG9 IE2) | 1EA |
| WY-NIBSC-21/284 | Anti-pneumococcal serotype 10A monoclonal antibody (clone 17-117IA3 IIB6) | 1EA |
| WY-NIBSC-21/286 | Anti-pneumococcal serotype 12F monoclonal antibody (clone 1C1) | 1EA |
| WY-NIBSC-21/288 | Anti-pneumococcal serotype 14 monoclonal antibody (clone 13-111A) | 1EA |
| WY-NIBSC-21/290 | Anti-pneumococcal serotype 18C monoclonal antibody (clone 15-104AG5 IIH4) | 1EA |
| WY-NIBSC-21/292 | Anti-pneumococcal serotype 19A monoclonal antibody (clone 14-105IH8 IE12) | 1EA |
| WY-NIBSC-21/294 | Anti-pneumococcal serotype 22F monoclonal antibody (clone 17-122 CG1 IC3) | 1EA |
| WY-NIBSC-21/298 | Influenza Virus Infectious A/Michigan/173/2020 (H3N2) | 1EA |
| WY-NIBSC-21/306 | Influenza Virus Infectious SAN-010 (H3N2) | 1EA |
| WY-NIBSC-21/308 | 2nd International Standard for Interleukin-6 | 1EA |
| WY-NIBSC-21/314 | Influenza Antigen A/Darwin/6/2021 (IVR-227) (H3N2) | 1EA |
| WY-NIBSC-21/316 | Influenza Antigen B/Austria/1359417/2021 (BVR-26) (B Victoria Lineage) | 1EA |
| WY-NIBSC-21/318 | Influenza Antigen A/Darwin/9/2021 (IVR-228) (H3N2) | 1EA |
| WY-NIBSC-21/320 | Influenza Antigen A/Darwin/9/2021 (SAN-010) (H3N2) | 1EA |
| WY-NIBSC-21/322 | Influenza Anti-B Neuraminidase Serum (B/Phuket/3073/2013) | 1EA |
| WY-NIBSC-21/326 | Influenza Anti-B/Austria/1359417/2021 Like (B Victoria Lineage) HA Serum | 1EA |
| WY-NIBSC-21/330 | Influenza Antigen B/Michigan/01/2021 | 1EA |
| WY-NIBSC-21/332 | 1st International Reference Panel for anti-Lassa fever virus antibodies | 1EA |
| WY-NIBSC-21/336 | Influenza Virus Infectious B/Washington/02/2019 (B-Victoria lineage) | 1EA |
| WY-NIBSC-21/338 | 1st International Standard 2022 Antibodies to SARS-CoV-2 variants of concern | 1EA |
| WY-NIBSC-21/340 | Second WHO International Standard for anti-SARS-CoV-2 immunoglobulin | 1EA |
| WY-NIBSC-21/346 | Influenza Virus Infectious A/Victoria/2570/2019 (H1N1) | 1EA |
| WY-NIBSC-21/348 | Influenza Virus Infectious B/Utah/9/2014 (B-Yamagata lineage) | 1EA |
| WY-NIBSC-21/350 | Influenza Virus Infectious BX-59A (B-Yamagata lineage) | 1EA |
| WY-NIBSC-21/352 | Influenza Virus Infectious B/Brisbane/9/2014 (B-Yamagata) | 1EA |
| WY-NIBSC-21/366 | Influenza Virus Infectious SAN-011 (H1N1) | 1EA |
| WY-NIBSC-21/368 | SARS-Cov-2 Antigen 1st WHO International Standard | 1EA |
| WY-NIBSC-21/380 | Influenza Virus Infectious IVR-208 (H3N2) | 1EA |
| WY-NIBSC-21/382 | Influenza Virus Infectious X-367A (H3N2) | 1EA |
| WY-NIBSC-21/384 | Influenza Virus Infectious X-369A (H3N2) | 1EA |
| WY-NIBSC-21/388 | Influenza Virus Infectious B/Guangdong-Zhenjiang/1516/2021 (B-Victoria Lineage) | 1EA |
| WY-NIBSC-21/B777 | Ferritin Quality Control Sample | 1EA |
| WY-NIBSC-21/B882 | QCRHSV1QC1-Anti-HSV1 Quality Control Serum: Sample1 | 1EA |
| WY-NIBSC-21/B889 | QCRHCVQC1-Anti-HCV Quality Control Serum: Sample1 | 1EA |
| WY-NIBSC-22/100 | Influenza Antigen A/Victoria/2570/2019 (IVR-215) (H1N1) | 1EA |
| WY-NIBSC-22/108 | Reference Panel for Lassa virus RNA | 1EA |
| WY-NIBSC-22/118 | Influenza Virus Infectious NIB-129 (H3N2) | 1EA |
| WY-NIBSC-22/134 | Influenza Virus Infectious BX-107A (B-Victoria Lineage) | 1EA |
| WY-NIBSC-22/136 | Influenza Virus Infectious A/North Carolina/01/2021 (H1N1) X-375 | 1EA |
| WY-NIBSC-22/138 | Influenza Virus Infectious A/Indiana/02/2020 (H1N1) | 1EA |
| WY-NIBSC-22/140 | Influenza Virus Infectious A/Netherlands 00007/2021 (H3N2) SAN-012 | 1EA |
| WY-NIBSC-22/142 | Influenza Virus Infectious A/Sydney/5/2021 (H1N1) SAN-013 | 1EA |
| WY-NIBSC-22/144 | Influenza Virus Infectious A/Darwin/22/2021 (H3N2) SAN-014 | 1EA |
| WY-NIBSC-22/146 | Influenza Virus Infectious A/Brisbane/02/2018 (H1N1) | 1EA |
| WY-NIBSC-22/148 | Meningococcal Capsular Group Y Polysaccharide | 1EA |
| WY-NIBSC-22/154 | Influenza Virus Infectious B/Connecticut/01/2021 (B-Victoria Lineage) | 1EA |
| WY-NIBSC-22/156 | Influenza Virus Infectious A/Norway/16606/2021 (H3N2) NYMC X-373A | 1EA |
| WY-NIBSC-22/158 | Influenza Virus Infectious A/Netherlands/00007/2021 (H3N2) NYMC X-377 | 1EA |
| WY-NIBSC-22/172 | Influenza Virus Infectious A/Lyon/820/2021 (H1N1) NIB-132 | 1EA |
| WY-NIBSC-22/174 | Influenza Virus Infectious A/Victoria/2570/2019 (H1N1) NYMC X-379 | 1EA |
| WY-NIBSC-22/178 | Influenza Virus Infectious A/Darwin/22/2021 (H3N2) NIB -130 | 1EA |
| WY-NIBSC-22/180 | Influenza Virus Infectious A/Guizhou/Liuzhite/326/2022 (H3N2) CNIC-2206 | 1EA |
| WY-NIBSC-22/200 | Influenza Virus Infectious A/Sydney/5/2021 (H1N1) | 1EA |
| WY-NIBSC-22/204 | Influenza Virus Infectious B/Austria/1359417/2021 (B-Victoria lineage) BVR-26 | 1EA |
| WY-NIBSC-22/212 | NIBSC Reference Reagent for DNA extractions of gut microbiome samples (WC-Gut-RR) | 1EA |
| WY-NIBSC-22/214 | Influenza Virus Infectious CBER-48A (A/Sydney/5/2021) (H1N1) | 1EA |
| WY-NIBSC-22/218 | Working Reagent for anti-monkeypox virus antibodies | 1EA |
| WY-NIBSC-22/220 | Influenza Antigen A/Sydney/5/2021 (SAN-013) (H1N1) | 1EA |
| WY-NIBSC-22/222 | Influenza Antigen A/Sydney/175/2022 (IVR-235) (H1N1) | 1EA |
| WY-NIBSC-22/226 | Influenza Anti-A/Darwin/9/2021-like (H3N2) HA Serum | 1EA |
| WY-NIBSC-22/234 | Influenza Virus Infectious IVR-235 (A/Sydney/175/2022 (H1N1) | 1EA |
| WY-NIBSC-22/236 | Anti-pneumococcal serotype 2 monoclonal antibody (clone 2D1) | 1EA |
| WY-NIBSC-22/238 | Anti-pneumococcal serotype 4 monoclonal antibody (clone 14-100JA2 IIE7 2H7) | 1EA |
| WY-NIBSC-22/242 | Anti-pneumococcal serotype 11A monoclonal antibody (clone 8G12) | 1EA |
| WY-NIBSC-22/244 | Anti-pneumococcal serotype 15B monoclonal antibody (clone 3D3) | 1EA |
| WY-NIBSC-22/246 | Anti-pneumococcal serotype 17F monoclonal antibody (clone 17-120DG2 IF2) | 1EA |
| WY-NIBSC-22/248 | Anti-pneumococcal serotype 20 monoclonal antibody (clone 18-121 DF9 IIG8 1B6) | 1EA |
| WY-NIBSC-22/250 | Anti-pneumococcal serotype 33F monoclonal antibody (clone 3B2) | 1EA |
| WY-NIBSC-22/254 | Anti-pneumococcal serotype 6C monoclonal antibody (clone 1B2) | 1EA |
| WY-NIBSC-22/256 | Anti-pneumococcal serotype 15A/B monoclonal antibody (clone 3A4) | 1EA |
| WY-NIBSC-22/258 | Anti-pneumococcal serotype 16F monoclonal antibody (clone 20-121HC4 IA4 IE6) | 1EA |
| WY-NIBSC-22/260 | Anti-pneumococcal serotype 19F monoclonal antibody (clone 8E9- 1B12) | 1EA |
| WY-NIBSC-22/262 | Anti-pneumococcal serotype 23F monoclonal antibody (clone 15-113HA6 IG2) | 1EA |
| WY-NIBSC-22/264 | Anti-pneumococcal serotype 24F monoclonal antibody (clone 1A6) | 1EA |
| WY-NIBSC-22/266 | Anti-pneumococcal serotype 35B monoclonal antibody (clone 3F6) | 1EA |
| WY-NIBSC-22/268 | Influenza Virus Infectious SAN-015 (A/Lyon/820/2021) (H1N1) | 1EA |
| WY-NIBSC-22/270 | 1st International Reference Panel for antibodies to SARS-CoV-2 variants of concern | 1EA |
| WY-NIBSC-22/272 | 1st International Reference Panel for Infliximab anti-drug antibodies | 1EA |
| WY-NIBSC-22/276 | Anti-pneumococcal serotype 2 monoclonal antibody (clone 1G7) | 1EA |
| WY-NIBSC-22/278 | Anti-pneumococcal serotype 15B monoclonal antibody (clone 2F4) | 1EA |
| WY-NIBSC-22/280 | Anti-pneumococcal serotype 23F monoclonal antibody (clone 15-113HA5 IE2 IE2) | 1EA |
| WY-NIBSC-22/282 | Anti-pneumococcal serotype 24F monoclonal antibody (clone 2F2) | 1EA |
| WY-NIBSC-22/284 | Anti-pneumococcal serotype CPS monoclonal antibody (clone 14-108BA5 IE10) | 1EA |
| WY-NIBSC-22/286 | Anti-pneumococcal serotype 4 monoclonal antibody (clone 14-100JA2 IIE7 2G6) | 1EA |
| WY-NIBSC-22/288 | Anti-pneumococcal serotype 5 monoclonal antibody (clone 1366KG3 IA11) | 1EA |
| WY-NIBSC-22/290 | Anti-pneumococcal serotype 6B monoclonal antibody (clone 14-102CC2 ID9) | 1EA |
| WY-NIBSC-22/292 | Anti-pneumococcal serotype 8 monoclonal antibody (clone 6G1) | 1EA |
| WY-NIBSC-22/294 | Anti-pneumococcal serotype 10A monoclonal antibody (clone 17-117DE8 IIE9) | 1EA |
| WY-NIBSC-22/296 | Anti-pneumococcal serotype 11A monoclonal antibody (clone 2E2) | 1EA |
| WY-NIBSC-22/298 | Anti-pneumococcal serotype 12F monoclonal antibody (clone 1C8) | 1EA |
| WY-NIBSC-22/300 | Anti-pneumococcal serotype 15A-B monoclonal antibody (clone 1B4) | 1EA |
| WY-NIBSC-22/302 | Anti-pneumococcal serotype 16F monoclonal antibody (clone 20-121EC11 IIF10 VE2) | 1EA |
| WY-NIBSC-22/304 | Anti-pneumococcal serotype 17F monoclonal antibody (clone 17-120AE4 IE3 IG2) | 1EA |
| WY-NIBSC-22/306 | Anti-pneumococcal serotype 22F monoclonal antibody (clone 17-122 JB11 IB11) | 1EA |
| WY-NIBSC-22/308 | Anti-pneumococcal serotype 35B monoclonal antibody (clone 3F9) | 1EA |
| WY-NIBSC-22/312 | Influenza Virus Infectious A/Norway/31694/2022 (H1N1) | 1EA |
| WY-NIBSC-22/316 | Influenza Virus Infectious A/Victoria/4897/2022 (H1N1) | 1EA |
| WY-NIBSC-22/318 | Influenza Virus Infectious IVR-238 (A/Victoria/4897/2022 (H1N1) | 1EA |
| WY-NIBSC-22/320 | Influenza Antigen A/Victoria/4897/2022 (IVR-238) (H1N1) | 1EA |
| WY-NIBSC-22/B891 | QCRTOXOIgMQC1 IgM Anti-Toxoplasma QC1 | 1EA |
| WY-NIBSC-22/B893 | QCRHBsGQC2-Anti HBsAg Quality Control Serum: Sample2 | 1EA |
| WY-NIBSC-22/B895 | QCRHIV2QC2-Anti HIV2: Quality Control Serum: Sample2 | 1EA |
| WY-NIBSC-22/B896 | Anti-SARS-CoV-2 Verification Panel for Serology Assays | 1EA |
| WY-NIBSC-23/100 | Influenza anti-A/Victoria/4897/2022-like (H1N1) HA Serum | 1EA |
| WY-NIBSC-23/112 | Influenza Virus Infectious NIB-133 (A/Norway/31694/2022) (H1N1) | 1EA |
| WY-NIBSC-23/120 | Influenza Virus Infectious A/Wisconsin/67/2022 (H1N1) | 1EA |
| WY-NIBSC-23/122 | Influenza Virus Infectious A/West Virginia/30/2022 (H1N1) | 1EA |
| WY-NIBSC-23/126 | Influenza Virus Infectious NIB-134 (A/Catalonia/NSVH161512065/2022 (H1N1) | 1EA |
| WY-NIBSC-234 | IPV ELISA MAbs Type 1, 2 and 3 (Type 1; No: 234) | 1EA |
| WY-NIBSC-2BADS | Anti-Brucella Abortus Serum, Bovine (International Standard) | 1EA |
| WY-NIBSC-2CPBETAAT | Clostridium Perfringens Beta Antitoxin (2nd International Standard) | 1EA |
| WY-NIBSC-2CPEPAT | Clostridium Perfringens Epsilon Antitoxin (2nd International Standard) | 1EA |
| WY-NIBSC-32-1 | Filamentous Haemagglutinin monoclonal antibody, clone 32-1 | 1EA |
| WY-NIBSC-3-5 | Pertactin Monoclonal antibody, Clone 3-5 | 1EA |
| WY-NIBSC-4024 | Antisera to SARS CoV-1 S1 Protein (Rabbit) | 1EA |
| WY-NIBSC-520 | IPV ELISA MAbs Type 1, 2 and 3 (Type 3; No: 520) | 1EA |
| WY-NIBSC-59/015 | Gas Gangrene (Cl. Perfringens(Cl. Welchii) Type A), Equine | 1EA |
| WY-NIBSC-59/016 | Corticotrophin (ACTH), Porcine (3rd International Standard) | 1EA |
| WY-NIBSC-59/021 | Botulinum Antitoxin Equine Type A | 1EA |
| WY-NIBSC-60/001 | Botulinum Antitoxin Equine Type B | 1EA |
| WY-NIBSC-60/013 | Tetanus Antitoxin, Equine, for Bioassay | 1EA |
| WY-NIBSC-62/014 | Lysine Vasopressin, Porcine | 1EA |
| WY-NIBSC-629E1 | Pertussis toxoid monoclonal antibody, clone 629E1 | 1EA |
| WY-NIBSC-63/005 | Gas Gangrene Antitoxin (Cl. Histolyticum), Equine | 1EA |
| WY-NIBSC-64/014 | Gas Gangrene Antitoxin (Cl. Septicum), Equine | 1EA |
| WY-NIBSC-64/024 | Gas Gangrene Antitoxin (Cl. Oedematiens), Equine | 1EA |
| WY-NIBSC-65/093 | Anti-Thyroglobulin Serum, Human (WHO Reference reagent) | 1EA |
| WY-NIBSC-65/119 | Renin, Porcine | 1EA |
| WY-NIBSC-65/122 | Long-acting Thyroid Stimulator, Human | 1EA |
| WY-NIBSC-66/138 | Gastrin II, Porcine | 1EA |
| WY-NIBSC-66/153 | Diphtheria Antitoxin, Equine | 1EA |
| WY-NIBSC-66/233 | Anti-Nuclear Factor Serum (Homogenous) Human | 1EA |
| WY-NIBSC-67/037 | Immunoglobulin D (IgD) Serum, Human | 1EA |
| WY-NIBSC-67/099 | Immunoglobulins G, A & M Serum Human | 1EA |
| WY-NIBSC-67/182 | Anti-Rubella Serum, Human | 1EA |
| WY-NIBSC-67/183 | Primary Biliary Cirrhosis Serum, Human | 1EA |
| WY-NIBSC-68/340 | Anti-Nucleolar Factor Plasma, Human | 1EA |
| WY-NIBSC-68/356 | Renin, Human (International Standard) | 1EA |
| WY-NIBSC-69/065 | Autoimmune Antibody to Human Spermatazoa | 1EA |
| WY-NIBSC-69/194 | Glucagon, Porcine (First International Standard) | 1EA |
| WY-NIBSC-69K/16 | Pertactin monoclonal antibody, clone 69K/16 | 1EA |
| WY-NIBSC-70/302 | Angiotensin II (25μg) | 1EA |
| WY-NIBSC-71/281 | Anti-Malaria Plasma P Vivax | 1EA |
| WY-NIBSC-71/326 | Anti-Malaria Plasma Vivax Ng2 | 1EA |
| WY-NIBSC-72/092 | Anti-malaria Plasma: Plasmodium falciparum (Ghana) | 1EA |
| WY-NIBSC-72/096 | Anti-Malaria Serum (P.Malariae) | 1EA |
| WY-NIBSC-72/341 | Anti-Malaria Plasma P Falciparum | 1EA |
| WY-NIBSC-72/345 | Anti-Malaria Plasma P Falciparum | 1EA |
| WY-NIBSC-72/348 | Anti-Malaria Plasma P Vivax | 1EA |
| WY-NIBSC-73/517 | Anti-D (Rho) Antibodies, Human | 1EA |
| WY-NIBSC-73/545 | Placental Lactogen, Human (International Reference Preparation) | 1EA |
| WY-NIBSC-73/554 | Cholera Vaccine (Inaba) | 1EA |
| WY-NIBSC-73/556 | Cholera Vaccine (Ogawa) | 1EA |
| WY-NIBSC-74/520 | Serum Proteins (Other than Immunoglobulins) Human | 1EA |
| WY-NIBSC-74/581 | Ancrod (1st International Reference Preparation) | 1EA |
| WY-NIBSC-75/506 | Cocksfoot Pollen Extract | 1EA |
| WY-NIBSC-75/533 | Chorionic Gonadotrophin, Human, for Radioiodination | 1EA |
| WY-NIBSC-75/535 | Chorionic Gonadotrophin beta, Human, for Radioiodination | 1EA |
| WY-NIBSC-75/551 | Chorionic Gonadotrophin beta Subunit, Human (International Reference Preparation) | 1EA |
| WY-NIBSC-75/569 | Chorionic Gonadotrophin alpha subunit, Human (International Reference Preparation) | 1EA |
| WY-NIBSC-75/595 | Blood Coagulation Factor Xa, Bovine | 1EA |
| WY-NIBSC-76/508 | Chorionic Gonadotrophin alpha Subunit, Human, for Radioiodination | 1EA |
| WY-NIBSC-76/515 | Mannan (Candida Albicans) Purified | 1EA |
| WY-NIBSC-76/522 | Opacity 5IRP WHO International Standard | 1EA |
| WY-NIBSC-76/525 | Anti-Birch Pollen Serum, Human | 1EA |
| WY-NIBSC-76/547 | Influenza anti A/Victoria/3/75 Serum(goat) | 1EA |
| WY-NIBSC-76/575 | Oxytocin(4th International Standard) | 1EA |
| WY-NIBSC-77/503 | Anti-Cocksfoot Serum, Human | 1EA |
| WY-NIBSC-77/512 | Lysine Vasopressin(1st International Standard) | 1EA |
| WY-NIBSC-77/531 | Influenza anti A/New Jersey/8/76(H1N1) Serum | 1EA |
| WY-NIBSC-77/568 | Influenza anti B/Hong Kong/8/73 Serum | 1EA |
| WY-NIBSC-77/584 | Anti-D Pteronyssinus Serum, Human | 1EA |
| WY-NIBSC-77/600 | Mannan (Candida Albicans) Purified | 1EA |
| WY-NIBSC-77/616 | Twelve Grass Pollen Extract | 1EA |
| WY-NIBSC-77/643 | Secretin | 1EA |
| WY-NIBSC-77/662 | Acarus Siro Extract | 1EA |
| WY-NIBSC-77/664 | Glycyphagus destructor Extract | 1EA |
| WY-NIBSC-78/517 | Tyrophagus Putrescentiae Extract | 1EA |
| WY-NIBSC-78/543 | Kininogenase (Porcine, Pancreatic) (Formerly 1st International Standard) | 1EA |
| WY-NIBSC-78/545 | Anti-Aspergillus fumigatus Serum, Human | 1EA |
| WY-NIBSC-78/554 | Luteinizing Hormone, Pituitary, alpha subunit (International Standard) | 1EA |
| WY-NIBSC-78/556 | Luteinizing Hormone, Pituitary, beta subunit (International standard) | 1EA |
| WY-NIBSC-78/560 | Influenza Antigen A/Texas/1/77 | 1EA |
| WY-NIBSC-78/569 | Influenza anti A/Texas/1/77 Serum | 1EA |
| WY-NIBSC-78/575 | Aspergillus Fumigatus Extract | 1EA |
| WY-NIBSC-78/582 | Tyrophagus Longior Extract | 1EA |
| WY-NIBSC-78/628 | Bee Venom | 1EA |
| WY-NIBSC-79/500 | Parathyroid Hormone, HumanRef. Preparation) | 1EA |
| WY-NIBSC-79/516 | Influenza anti A/Brazil/11/78 Serum (goat) | 1EA |
| WY-NIBSC-79/552 | Influenza Antigen A/USSR/92/77 | 1EA |
| WY-NIBSC-79/558 | Influenza Antigen A/USSR/92/77 | 1EA |
| WY-NIBSC-79/560 | Influenza Antigen A/Brazil/11/78 | 1EA |
| WY-NIBSC-79/568 | Influenza Antigen B/Hong Kong/8/73 | 1EA |
| WY-NIBSC-79/572 | Prekallikrein Activator (PKA), Human | 1EA |
| WY-NIBSC-80/505 | Growth Hormone, Human, Pituitary. WHO International Standard | 1EA |
| WY-NIBSC-80/517 | Influenza Antigen A/Bangkok/1/79 | 1EA |
| WY-NIBSC-80/519 | Influenza Antigen B/Singapore/222/79 | 1EA |
| WY-NIBSC-80/523 | Influenza anti B/Singapore/222/79 Serum | 1EA |
| WY-NIBSC-80/525 | Influenza anti A/Bangkok/1/79 Serum | 1EA |
| WY-NIBSC-80/590 | Tetracosactide. International Ref. Preparation | 1EA |
| WY-NIBSC-81/535 | Luteinizing Hormone, Human, Pituitary (3rd International Standard) | 1EA |
| WY-NIBSC-82/508 | Parathyroid Hormone, Human-Type, Synthetic (1-34) fragment | 1EA |
| WY-NIBSC-82/512 | Parathyroid Hormone, Bovine-Type, Synthetic (1-34) fragment | 1EA |
| WY-NIBSC-82/518 | Dermatophagoides Pteronyssinus Extract. WHO International Standard | 1EA |
| WY-NIBSC-82/520 | Timothy Pollen Extract. WHO International Standard | 1EA |
| WY-NIBSC-82/585 | Anti Poliovirus serum types 1,2 and 3 (3rd International Standard) | 1EA |
| WY-NIBSC-82/587 | Interferon Gamma (Human, Leukocyte derived) | 1EA |
| WY-NIBSC-82/632 | Parathyroid Hormone, Bovine. WHO International Standard | 1EA |
| WY-NIBSC-82/652 | Human Serum Vitamin B12, Pernicous anaemia | 1EA |
| WY-NIBSC-83/501 | Beta Thromboglobulin, Purified Human. WHO International Standard | 1EA |
| WY-NIBSC-83/505 | Platelet Factor 4 Human, Purified. WHO International Standard | 1EA |
| WY-NIBSC-83/511 | Insulin, Bovine. WHO International Standard | 1EA |
| WY-NIBSC-83/514 | Interferon alpha-1D, (Human rDNA derived) WHO International Standard | 1EA |
| WY-NIBSC-83/515 | Insulin, Porcine. WHO International Standard | 1EA |
| WY-NIBSC-83/537 | Influenza Antigen A/Philippines/2/82 | 1EA |
| WY-NIBSC-83/545 | Influenza anti A/Philippine/2/82 Serum | 1EA |
| WY-NIBSC-83/550 | Influenza Antigen A/Brazil/11/78 | 1EA |
| WY-NIBSC-83/573 | Prolactin, Human (4th WHO International Standard) | 1EA |
| WY-NIBSC-83/575 | Follicle Stimulating Hormone, Pituitary. WHO International Standard | 1EA |
| WY-NIBSC-84/514 | Proinsulin, Bovine. International Ref. Preparation | 1EA |
| WY-NIBSC-84/522 | Birch Pollen Extract. WHO International Standard | 1EA |
| WY-NIBSC-84/528 | Proinsulin, Porcine. International Ref. Reagent | 1EA |
| WY-NIBSC-84/538 | Influenza Antigen A/Chile/1/83 | 1EA |
| WY-NIBSC-84/542 | Influenza Antigen B/Norway/1/84 | 1EA |
| WY-NIBSC-84/581 | Short Ragweed Pollen Extract. WHO International Standard | 1EA |
| WY-NIBSC-84/614 | Calcitonin, ASU 1-7 Eel Calcitonin Analogue (Elcatonin) WHO International Standard | 1EA |
| WY-NIBSC-84/628 | Anti-c Serum, Human | 1EA |
| WY-NIBSC-84/636 | Influenza anti B/USSR/100/83 Serum | 1EA |
| WY-NIBSC-84/640 | Influenza anti A/Chile/1/8 Serum | 1EA |
| WY-NIBSC-84/677 | Influenza anti A/equine/Miami/63 (H3N8) Serum(goat) | 1EA |
| WY-NIBSC-84/685 | Dog (Canis Familiaris) Hair Dander Extract. WHO International Standard | 1EA |
| WY-NIBSC-85/506 | C-Reactive Protein, Human. WHO International Standard | 1EA |
| WY-NIBSC-85/516 | Influenza anti A/Equine/Kentucky/1/81 HA Serum | 1EA |
| WY-NIBSC-85/520 | Influenza Antigen A/Equine/Kentucky/1/81 | 1EA |
| WY-NIBSC-85/522 | Thyroid Stimulating Hormone beta subunit | 1EA |
| WY-NIBSC-85/551 | Anti-Rye Grass Serum, Human | 1EA |
| WY-NIBSC-85/616 | Haemoglobin F Lysate, Raised. WHO Reference Reagent | 1EA |
| WY-NIBSC-85/669 | Atrial Natriuretic Factor, Human. WHO International Standard | 1EA |
| WY-NIBSC-86/500 | Interleukin- 2 (Human, rDNA derived)(2nd International Standard) | 1EA |
| WY-NIBSC-86/536 | Angiotensin I Human Type Synthetic | 1EA |
| WY-NIBSC-86/538 | Angiotensin II (2.5μg) | 1EA |
| WY-NIBSC-86/552 | Interleukin-1 Beta (Human, rDNA derived) | 1EA |
| WY-NIBSC-86/576 | Influenza Antigen A/Mississippi/1/85 | 1EA |
| WY-NIBSC-86/590 | Influenza anti A/Mississippi/1/85 Serum | 1EA |
| WY-NIBSC-86/592 | Influenza anti B/Ann Arbor/1/86/HA Serum | 1EA |
| WY-NIBSC-86/630 | Influenza Antigen B/Ann Arbor/ 1/86 | 1EA |
| WY-NIBSC-86/632 | Interleukin-1 alpha (Human rDNA derived) WHO International Standard | 1EA |
| WY-NIBSC-86/678 | Interleukin-1 alpha (Human, rDNA derived) | 1EA |
| WY-NIBSC-86/680 | Interleukin-1 beta (Human, rDNA derived) WHO International Standard | 1EA |
| WY-NIBSC-86/690 | Inhibin, Porcine WHO International Standard | 1EA |
| WY-NIBSC-87/510 | Influenza Antigen A/Equine/Miami/63 | 1EA |
| WY-NIBSC-87/578 | Influenza anti A/Leningrad/360/86 Serum | 1EA |
| WY-NIBSC-87/584 | Influenza Antigen A/Leningrad/360/86 | 1EA |
| WY-NIBSC-87/586 | Interferon Gamma (Human, rDNA derived) | 1EA |
| WY-NIBSC-87/640 | Tumour Necrosis Factor beta (Human, rDNA derived) WHO Reference Reagent | 1EA |
| WY-NIBSC-87/654 | Anti-Ferritin Monoclonal Antibody (1) | 1EA |
| WY-NIBSC-87/662 | Anti-Ferritin Monoclonal Antibody (2) | 1EA |
| WY-NIBSC-87/714 | Influenza Antigen A/Sichuan/2/87 | 1EA |
| WY-NIBSC-87/774 | Influenza Antigen B/Victoria/2/87 | 1EA |
| WY-NIBSC-88/522 | Bordetella pertussis (Whole cell vaccine) 3BRP | 1EA |
| WY-NIBSC-88/532 | Tumour Necrosis Factor alpha (Mouse, rDNA derived) | 1EA |
| WY-NIBSC-88/554 | Influenza Antigen B/Beijing/1/87 | 1EA |
| WY-NIBSC-88/556 | Calcitonin, Eel WHO International Standard | 1EA |
| WY-NIBSC-88/638 | Thyroxine-binding globulin. WHO International Standard | 1EA |
| WY-NIBSC-88/646 | Granulocyte Macrophage Colony Stimulating Factor (Human, rDNA derived) WHO International Standard | 1EA |
| WY-NIBSC-88/654 | Influenza Antigen A/England/427/88 | 1EA |
| WY-NIBSC-88/656 | Interleukin-4 (Human, rDNA derived) WHO International Standard | 1EA |
| WY-NIBSC-88/672 | Influenza anti A/Sichuan/2/87 Serum | 1EA |
| WY-NIBSC-88/678 | Influenza anti B/Beijing/1/87 Serum | 1EA |
| WY-NIBSC-88/846 | Influenza anti A/England/427/88 Serum | 1EA |
| WY-NIBSC-89/512 | Macrophage Colony Stimulating Factor (CSF-1) (Human rDNA derived) WHO International Standard | 1EA |
| WY-NIBSC-89/514 | Transforming Growth Factor beta-1 (Human, rDNA derived) | 1EA |
| WY-NIBSC-89/516 | Transforming Growth Factor beta-1 (Bovine) | 1EA |
| WY-NIBSC-89/518 | Transforming Growth Factor beta-2 (Bovine) | 1EA |
| WY-NIBSC-89/520 | Interleukin-8 (Human, rDNA derived) WHO International Standard | 1EA |
| WY-NIBSC-89/530 | Anti-Bordetella pertussis serum (Human) | 1EA |
| WY-NIBSC-89/544 | Renin, Human, rec DNA | 1EA |
| WY-NIBSC-89/568 | Influenza Antigen A/OMS/5389/88 | 1EA |
| WY-NIBSC-89/594 | Bordetella pertussis (W28) LPS 2ug | 1EA |
| WY-NIBSC-89/596 | Bordetella pertussis anti-agglutinogen 1(rabbit) | 1EA |
| WY-NIBSC-89/598 | Bordetella pertussis anti-agglutinogen 2 (rabbit) | 1EA |
| WY-NIBSC-89/600 | Bordetella pertussis anti-agglutinogen 3 (rabbit) | 1EA |
| WY-NIBSC-89/620 | Calcitonin, Human. WHO International Standard | 1EA |
| WY-NIBSC-89/666 | Haemoglobin A2 Lysate, Raised. WHO Reference Reagent | 1EA |
| WY-NIBSC-89/670 | Bordetella pertussis (W28) LPS25ug | 1EA |
| WY-NIBSC-8E1-1H1.2.1 | Tetanus toxoid monoclonal antibody, clone 8E1-1H1.2.1 | 1EA |
| WY-NIBSC-90/500 | Influenza Antigen A/Shanghai/16/89 | 1EA |
| WY-NIBSC-90/502 | Influenza Antigen A/Guizhou/54/89 | 1EA |
| WY-NIBSC-90/504 | Influenza anti A/Guangdong/39/89 Serum | 1EA |
| WY-NIBSC-90/520 | Bordetella pertussis, filamentous haemagglutinin (FHA) | 1EA |
| WY-NIBSC-90/530 | Interleukin-7 (Human, rDNA derived) WHO Reference Reagent | 1EA |
| WY-NIBSC-90/534 | Mumps Vaccine (Live) WHO Reference Reagent | 1EA |
| WY-NIBSC-90/586 | Interleukin-5 (Human, rDNA derived) WHO Reference Reagent | 1EA |
| WY-NIBSC-90/636 | HIV-1 P24 Antigen WHO International Standard | 1EA |
| WY-NIBSC-90/690 | Anti-Varicella-Zoster Antibody | 1EA |
| WY-NIBSC-90/696 | Transforming Growth Factor beta-2, Human, rec DNA | 1EA |
| WY-NIBSC-90/712 | Basic Fibroblast Growth Factor (Human, rDNA derived) WHO International Standard | 1EA |
| WY-NIBSC-90/784 | Influenza Virus infectious NIB-26 (H3N2) | 1EA |
| WY-NIBSC-91/510 | Interleukin-3 (Human, rDNA derived) WHO International Standard | 1EA |
| WY-NIBSC-91/530 | Epidermal Growth Factor (Human, rDNA derived) WHO International Standard | 1EA |
| WY-NIBSC-91/550 | Epidermal Growth Factor (1-52) (Human, rDNA derived) WHO Reference Reagent | 1EA |
| WY-NIBSC-91/554 | Insulin-like growth Factor 1 WHO International Standard | 1EA |
| WY-NIBSC-91/612 | Influenza anti A/Taiwan/1/86 Serum | 1EA |
| WY-NIBSC-91/624 | Recombinant Human Inhibin | 1EA |
| WY-NIBSC-91/626 | Activin A, Human, Recombinant. WHO Reference Reagent | 1EA |
| WY-NIBSC-91/656 | Interleukin-4 (Mouse, rDNA derived) | 1EA |
| WY-NIBSC-91/658 | Granulocyte Macrophage Colony Stimulating Factor (Mouse rDNA derived) | 1EA |
| WY-NIBSC-91/662 | Interleukin-3 (Mouse, rDNA derived) | 1EA |
| WY-NIBSC-91/670 | Influenza Virus infectious NIB-27 (H1N1) | 1EA |
| WY-NIBSC-91/678 | Interleukin-9 (Human,rDNA derived) WHO Reference Reagent | 1EA |
| WY-NIBSC-91/682 | Stem Cell Factor (Human rDNA derived) WHO Reference Reagent | 1EA |
| WY-NIBSC-91/688 | Rubella Vaccine (Live) 1st International Reference Reagent | 1EA |
| WY-NIBSC-92/510 | Follicle Stimulating Hormone, Human, recombinant. (WHO International Standard) | 1EA |
| WY-NIBSC-92/512 | Follicle Stimulating Hormone, urofollitropin Human Urinary WHO International Standard | 1EA |
| WY-NIBSC-92/518 | Macrophage Inflammatory Protein-1 alpha (Human, rDNA derived) | 1EA |
| WY-NIBSC-92/520 | Rantes (Human, rDNA derived) | 1EA |
| WY-NIBSC-92/530 | Influenza Antigen A/Texas/36/91 | 1EA |
| WY-NIBSC-92/582 | Influenza anti B/Yamagata/16/88 Serum | 1EA |
| WY-NIBSC-92/628 | Influenza Antigen B/Yamagata/16/88 | 1EA |
| WY-NIBSC-92/632 | Influenza anti A/Beijing/352/89 (H3N2) Serum | 1EA |
| WY-NIBSC-92/644 | Interleukin-1 Receptor Antagonist (IL-1ra) (Human, rDNA derived) | 1EA |
| WY-NIBSC-92/648 | Measles Vaccine (Live) 2nd International Reference Reagent | 1EA |
| WY-NIBSC-92/654 | Plasminogen Activator Inhibitor-1 (PAI-1), plasma Human WHO International Standard | 1EA |
| WY-NIBSC-92/658 | Papain preparation for use with Anti-D preparation 91/562 | 1EA |
| WY-NIBSC-92/734 | Influenza Virus infectious A/Beijing/32/92 (H3N2) | 1EA |
| WY-NIBSC-92/738 | Influenza Virus infectious A/Shanghai/24/90 | 1EA |
| WY-NIBSC-92/788 | Interleukin-11 (Human, rDNA derived) WHO Reference Reagent | 1EA |
| WY-NIBSC-92/794 | Monocyte Chemoattractant Protein-1 (Human,rDNA derived) | 1EA |
| WY-NIBSC-93/500 | Influenza Antigen A/Beijing/32/92 | 1EA |
| WY-NIBSC-93/516 | Influenza Antigen A/Shanghai/24/90 | 1EA |
| WY-NIBSC-93/518 | Influenza anti A/Beijing/32/92 (H3N2) Serum | 1EA |
| WY-NIBSC-93/522 | Influenza anti A/Shanghai/24/90 (H3N2) Serum | 1EA |
| WY-NIBSC-93/556 | Nerve Growth Factor (Human, rDNA derived) WHO Reference Reagent | 1EA |
| WY-NIBSC-93/560 | Insulin-like growth Factor Binding Protein-3 | 1EA |
| WY-NIBSC-93/562 | Leukaemia Inhibitory Factor (Human, rDNA derived) WHO Reference Reagent | 1EA |
| WY-NIBSC-93/564 | Oncostatin M (Human, rDNA derived) WHO Reference Reagent | 1EA |
| WY-NIBSC-93/566 | Interleukin-2 (Mouse, rDNA derived) | 1EA |
| WY-NIBSC-93/568 | Influenza Virus infectious A/Beijing/359/89 (H3N2) | 1EA |
| WY-NIBSC-93/574 | Bone morphogenetic Protein-2 (Human, rDNA derived) WHO Reference Reagent | 1EA |
| WY-NIBSC-93/668 | Interleukin-1 beta (Mouse, rDNA derived) | 1EA |
| WY-NIBSC-93/672 | Interleukin-1 alpha (Mouse, rDNA derived) | 1EA |
| WY-NIBSC-93/692 | Influenza Virus infectious B/Panama/45/90 | 1EA |
| WY-NIBSC-93/722 | Interleukin-10 (Human rDNA derived) WHO Reference Reagent | 1EA |
| WY-NIBSC-93/730 | Interleukin-6 (Mouse, rDNA derived) | 1EA |
| WY-NIBSC-93/740 | Interleukin-7 (Mouse, rDNA derived) | 1EA |
| WY-NIBSC-93/816 | Influenza Virus infectious A/Harbin/15/92 (H3N2) | 1EA |
| WY-NIBSC-94/500 | Influenza Antigen B/Panama/45/90 | 1EA |
| WY-NIBSC-94/504 | Influenza anti A/Shanghai/9/93 Serum | 1EA |
| WY-NIBSC-94/516 | Influenza Antigen A/Shangdong/9/93 | 1EA |
| WY-NIBSC-94/520 | Influenza anti B/Panama/45/90 Serum | 1EA |
| WY-NIBSC-94/532 | Pertussis Vaccine (Whole Cell) WHO International Standard | 1EA |
| WY-NIBSC-94/622 | Interleukin-13 (Human, rDNA derived) WHO Reference Reagent | 1EA |
| WY-NIBSC-94/674 | Thyroid Stimulating Hormone, Human recombinant WHO Reference Reagent | 1EA |
| WY-NIBSC-94/684 | Ciliary Neurotrophic Factor (Human, rDNA derived) WHO Reference Reagent | 1EA |
| WY-NIBSC-94/718 | Staphylokinase, rec (STAR) | 1EA |
| WY-NIBSC-94/728 | Platelet-derived Growth Factor-BB (Human, rDNA derived) WHO International Standard | 1EA |
| WY-NIBSC-94/730 | Tissue Plasminogen Activator (tPA) Antigen in Plasma WHO International Standard | 1EA |
| WY-NIBSC-94/754 | Interferon Omega (Human, rDNA derived) WHO International Standard | 1EA |
| WY-NIBSC-94/762 | Influenza Virus infectious RESVIR-8 (H3N2) | 1EA |
| WY-NIBSC-94/766 | Influenza Virus infectious NIB-34 (H3N2) | 1EA |
| WY-NIBSC-94/784 | Interferon alpha (Human, leukocyte derived)WHO International Standard | 1EA |
| WY-NIBSC-94/786 | Interferon alpha Concensus Sequence (Human rDNA derived) WHO International Standard | 1EA |
| WY-NIBSC-94/790 | MAPREC analysis of Poliovirus type 3 (Sabin). Synthetic DNA 100% 472-C WHO International Standard | 1EA |
| WY-NIBSC-95/510 | Influenza Antigen A/Texas/36/91 | 1EA |
| WY-NIBSC-95/516 | Influenza Antigen A/Johannesburg/33/94 | 1EA |
| WY-NIBSC-95/522 | Anti-HBc (Anti-hepatitis B core antigen) WHO International Standard | 1EA |
| WY-NIBSC-95/524 | Influenza anti A/Johannesburg/33/94 Serum | 1EA |
| WY-NIBSC-95/528 | Folate, Whole Blood Haemolysate WHO International Standard | 1EA |
| WY-NIBSC-95/542 | MAPREC analysis of Poliovirus type 3 (Sabin) Synthetic DNA 0.9% 472-C WHO International Standard | 1EA |
| WY-NIBSC-95/544 | Interleukin-12 (Human, rDNA derived) WHO Reference Reagent | 1EA |
| WY-NIBSC-95/554 | Interleukin-15 (Human, rDNA derived) WHO Reference Reagent | 1EA |
| WY-NIBSC-95/564 | Single Chain Urinary-Type Plasminogen Activator (SCuPA), (Non-Glyc) | 1EA |
| WY-NIBSC-95/568 | Interferon Alpha n1 (Human lymphoblastoid cell derived) WHO International Standard | 1EA |
| WY-NIBSC-95/572 | Interferon alpha-1/8 (Human, rDNA derived) WHO International Standard | 1EA |
| WY-NIBSC-95/574 | Interferon Alpha n3 (Human, leukocyte derived) WHO International Standard | 1EA |
| WY-NIBSC-95/580 | Interferon alpha-2c (Human, rDNA derived) WHO International Standard | 1EA |
| WY-NIBSC-95/646 | Parathyroid Hormone 1-84, human, recombinant (1st International Standard) | 1EA |
| WY-NIBSC-95/650 | Interferon alpha-2a (Human, rDNA derived) WHO International Standard | 1EA |
| WY-NIBSC-95/656 | Interferon alpha 2b (Human rDNA derived)(3rd International Standard) | 1EA |
| WY-NIBSC-95/668 | Single Chain Urinary-Type Plasminogen Activator (SCuPA), (Glyc) | 1EA |
| WY-NIBSC-95/674 | Anti-Meningococcal Serogroup A mAb | 1EA |
| WY-NIBSC-95/678 | Anti-Meningococcal Serogroup C mAb | 1EA |
| WY-NIBSC-96/528 | Soluble Tumour Necrosis Factor Receptor Type 1, (Human, rDNA derived) | 1EA |
| WY-NIBSC-96/532 | FMS-like tyrosine kinase 3 ligand (Human, rDNA derived) WHO Reference Reagent | 1EA |
| WY-NIBSC-96/534 | Brain-derived Neurotrophic Factor (Human, rDNA derived) WHO Reference Reagent | 1EA |
| WY-NIBSC-96/538 | Insulin-like growth Factor-II (Human rDNA derived) WHO Reference Reagent | 1EA |
| WY-NIBSC-96/556 | Hepatocyte Growth Factor/Scatter Factor (precursor), (Human rDNA derived) WHO International Standard | 1EA |
| WY-NIBSC-96/564 | Hepatocyte Growth Factor/Scatter Factor (Human, rDNA derived) WHO Reference Reagent | 1EA |
| WY-NIBSC-96/572 | MAPREC analysis of Poliovirus type 3 (Sabin) Low virus reference 0.7%472-C WHO Reference Reagent | 1EA |
| WY-NIBSC-96/578 | MAPREC analysis of Poliovirus type 3 (Sabin) High virus reference 1.1%472-C WHO Reference Reagent | 1EA |
| WY-NIBSC-96/602 | Luteinizing Hormone, Human, recombinant WHO International Standard | 1EA |
| WY-NIBSC-96/784 | Inhibin B, Human WHO Reference Reagent | 1EA |
| WY-NIBSC-96/836 | Influenza Virus infectious RESVIR-9 (H3N2) | 1EA |
| WY-NIBSC-96/850 | Influenza Virus infectious NIB-39 (H1N1) | 1EA |
| WY-NIBSC-97/518 | Influenza Antigen A/Johannesburg/82/96 | 1EA |
| WY-NIBSC-97/538 | Anti-Granulocyte Macrophage Colony Stimulating Factor Serum | 1EA |
| WY-NIBSC-97/550 | Islet Cell Antibodies WHO Reference Reagent | 1EA |
| WY-NIBSC-97/558 | Bordetella pertussis anti 69kD serum (sheep) | 1EA |
| WY-NIBSC-97/562 | Blood Coagulation Factors IXa Concentrate, Human, recombinant(1st I.S.) | 1EA |
| WY-NIBSC-97/564 | Bordetella pertussis anti FHA serum (sheep) | 1EA |
| WY-NIBSC-97/572 | Bordetella pertussis PT anti serum (sheep) | 1EA |
| WY-NIBSC-97/574 | Bordetella pertussis anti Fim3 serum (sheep) | 1EA |
| WY-NIBSC-97/584 | Influenza Antigen A/Equine/Newmarket/2/93 | 1EA |
| WY-NIBSC-97/594 | Leptin, Human, Recombinant WHO International Standard | 1EA |
| WY-NIBSC-97/596 | Influenza Antigen A/Equine/Newmarket/1/93 | 1EA |
| WY-NIBSC-97/600 | Interleukin-2 Soluble Receptor (human, rDNA derived) | 1EA |
| WY-NIBSC-97/610 | Influenza anti A/equine/Newmarket/1/93 Serum | 1EA |
| WY-NIBSC-97/612 | Influenza anti- A/Nanchang/933/95 (H3N2) HA serum | 1EA |
| WY-NIBSC-97/614 | Influenza anti A/Equine/Newmarket/2/93 (H3N8) HA Serum (SH-376) | 1EA |
| WY-NIBSC-97/626 | Leptin, Mouse, Recombinant WHO International Standard | 1EA |
| WY-NIBSC-97/642 | Bordetella pertussis anti serum (mouse) 1RR | 1EA |
| WY-NIBSC-97/646 | Anti-Hepatitis A Immunoglobulin, Human (W1041) WHO International Standard | 1EA |
| WY-NIBSC-97/648 | Anti-Measles serum (3rd International Standard) | 1EA |
| WY-NIBSC-97/692 | Influenza Virus infectious IVR-108 (H3N2) | 1EA |
| WY-NIBSC-97/714 | Prolactin, Human, recombinant. WHO Reference Reagent | 1EA |
| WY-NIBSC-97/722 | Influenza Virus infectious A/duck/Sing-Q/119/97 (H5N3) | 1EA |
| WY-NIBSC-97/748 | Influenza Antigen B/Harbin/7/94 | 1EA |
| WY-NIBSC-97/756 | MAPREC analysis of Poliovirus type 2 (Sabin), low virus reference 0.65%481-G. WHO Reference Reagent | 1EA |
| WY-NIBSC-97/758 | MAPREC analysis of Poliovirus type 2 (Sabin) Synthetic DNA 0.67%481-G WHO International Standard | 1EA |
| WY-NIBSC-97/760 | Influenza Antigen A/Beijing/262/95 | 1EA |
| WY-NIBSC-98/524 | MAPREC analysis of Poliovirus type 2 (Sabin) Synthetic DNA, 100%481-G WHO International Standard | 1EA |
| WY-NIBSC-98/544 | Influenza Virus infectious RESVIR-13 (H3N2) | 1EA |
| WY-NIBSC-98/572 | Diphtheria and Tetanus Antitoxin, Guinea Pig Serum | 1EA |
| WY-NIBSC-98/574 | Somatropin WHO International Standard | 1EA |
| WY-NIBSC-98/580 | Prolactin Human, recombinant, glycosylated WHO Reference Reagent | 1EA |
| WY-NIBSC-98/582 | Prolactin, Human, recombinant, non-glycosylated WHO Reference Reagent | 1EA |
| WY-NIBSC-98/586 | Calcitonin, Salmon. WHO International Standard | 1EA |
| WY-NIBSC-98/596 | MAPREC analysis of Poliovirus type 2 (Sabin), high virus reference 1.21% 481-G. WHO Reference Reagent | 1EA |
| WY-NIBSC-98/600 | Influenza Virus infectious NIB-40 (H5N3) | 1EA |
| WY-NIBSC-98/604 | Influenza anti B/Harbin/7/94/HA Serum | 1EA |
| WY-NIBSC-98/610 | Influenza Virus infectious ARIV-1 (H5N3) | 1EA |
| WY-NIBSC-98/666 | Influenza anti A/Hong Kong/489/97 (H5N1) Serum (sheep) | 1EA |
| WY-NIBSC-98/686 | Negative Control Guinea Pig Serum (Diphtheria and Tetanus Serology) | 1EA |
| WY-NIBSC-98/708 | Haemiglobincyanide WHO International Standard | 1EA |
| WY-NIBSC-98/714 | Tissue Plasminogen Activator, Human, Recombinant WHO International Standard | 1EA |
| WY-NIBSC-98/718 | Neurotrophin 3 | 1EA |
| WY-NIBSC-98/762 | Influenza Virus infectious Resvir-14 (H3N2) | 1EA |
| WY-NIBSC-98/772 | Influenza anti A/Beijing/262/95 Serum | 1EA |
| WY-NIBSC-98/774 | Influenza Antigen B/Shangdong/7/97 | 1EA |
| WY-NIBSC-99/506 | Anti-PT S1 subunit Monoclonal Antibody (1B7) | 1EA |
| WY-NIBSC-99/508 | Anti-PT S1 subunit Monoclonal Antibody (1D7) | 1EA |
| WY-NIBSC-99/510 | Anti-PT S1 subunit Monoclonal Antibody (3F11) | 1EA |
| WY-NIBSC-99/512 | Anti-PT S1 subunit Monoclonal Antibody (10D6) | 1EA |
| WY-NIBSC-99/516 | Anti-PT S1 subunit Monoclonal Antibody (E1E) | 1EA |
| WY-NIBSC-99/518 | Anti-PT S1 subunit Monoclonal Antibody (E2E) | 1EA |
| WY-NIBSC-99/520 | Anti-PT S1 subunit Monoclonal Antibody (3F10) | 1EA |
| WY-NIBSC-99/522 | Anti-PT S1 subunit Monoclonal Antibody (11D9) | 1EA |
| WY-NIBSC-99/524 | Anti-PT S1 subunit Monoclonal Antibody (4D10) | 1EA |
| WY-NIBSC-99/526 | Anti-PT S23 subunit Monoclonal Antibody (11E6) | 1EA |
| WY-NIBSC-99/528 | Anti-PT S23 subunit Monoclonal Antibody (10C9) | 1EA |
| WY-NIBSC-99/530 | Anti-PT S23 subunit Monoclonal Antibody (10B5) | 1EA |
| WY-NIBSC-99/532 | Anti-PT S23 subunit Monoclonal Antibody (G9A) | 1EA |
| WY-NIBSC-99/534 | Anti-PT S23 subunit Monoclonal Antibody (3F6) | 1EA |
| WY-NIBSC-99/536 | Anti-PT S2 subunit Monoclonal Antibody (3A12) | 1EA |
| WY-NIBSC-99/538 | Anti-PT S2 subunit Monoclonal Antibody (2H3) | 1EA |
| WY-NIBSC-99/540 | Anti-PT S2 subunit Monoclonal Antibody (9G8) | 1EA |
| WY-NIBSC-99/542 | Anti-PT S3 subunit Monoclonal Antibody (7E10) | 1EA |
| WY-NIBSC-99/544 | Anti-PT S3 subunit Monoclonal Antibody (7G11) | 1EA |
| WY-NIBSC-99/546 | Anti-PT S3 subunit Monoclonal Antibody (4G5) | 1EA |
| WY-NIBSC-99/548 | Anti-PT S3 subunit Monoclonal Antibody (2E12) | 1EA |
| WY-NIBSC-99/550 | Anti-PT S3 subunit Monoclonal Antibody (6F8) | 1EA |
| WY-NIBSC-99/552 | Anti-PT S3 subunit Monoclonal Antibody (10B8) | 1EA |
| WY-NIBSC-99/554 | Anti-PT S4 subunit Monoclonal Antibody (7F2) | 1EA |
| WY-NIBSC-99/556 | Anti-PT S4 subunit Monoclonal Antibody (6B3) | 1EA |
| WY-NIBSC-99/558 | Anti-PT S4 subunit Monoclonal Antibody (6G8) | 1EA |
| WY-NIBSC-99/560 | Anti-PT S4 subunit Monoclonal Antibody (9F3) | 1EA |
| WY-NIBSC-99/562 | Anti-PT S4 subunit Monoclonal Antibody (1H2) | 1EA |
| WY-NIBSC-99/564 | Anti-PT S4 subunit Monoclonal Antibody (9C6) | 1EA |
| WY-NIBSC-99/566 | Anti-PT S4 subunit Monoclonal Antibody (6D6) | 1EA |
| WY-NIBSC-99/568 | Anti-PT S5 subunit Monoclonal Antibody (7E3) | 1EA |
| WY-NIBSC-99/570 | Anti Filamentous Haemagglutinin Monoclonal Antibody (1C6) | 1EA |
| WY-NIBSC-99/572 | Anti-Filamentous Haemagglutinin Monoclonal Antibody (2E9) | 1EA |
| WY-NIBSC-99/574 | Anti Filamentous Haemagglutinin Monoclonal Antibody (12G10) | 1EA |
| WY-NIBSC-99/586 | Influenza Antigen B/Yamanashi/166/98 | 1EA |
| WY-NIBSC-99/614 | Influenza Antigen A/Sydney/5/97 | 1EA |
| WY-NIBSC-99/616 | Yellow Fever Vaccine. WHO International Standard | 1EA |
| WY-NIBSC-99/624 | Influenza Antigen A/Sydney/5/97 | 1EA |
| WY-NIBSC-99/642 | Chorionic Gonadotrophin, nicked, human. WHO Reference Reagent | 1EA |
| WY-NIBSC-99/650 | Chorionic Gonadotrophin, beta subunit, human. WHO Reference Reagent | 1EA |
| WY-NIBSC-99/666 | Anti-HPA-5b (Minimum Potency) WHO Reference Reagent | 1EA |
| WY-NIBSC-99/674 | HIV-2 (antibody) Monitor Sample | 1EA |
| WY-NIBSC-99/688 | Chorionic Gonadatrophin, intact, Human. WHO Reference Reagent | 1EA |
| WY-NIBSC-99/692 | Chorionic Gonadotrophin, nicked beta subunit, Human WHO Reference Reagent | 1EA |
| WY-NIBSC-99/706 | Anti-Meningococcal human reference serum CDC1992 | 1EA |
| WY-NIBSC-99/708 | Chorionic Gonadatrophin, beta core fragment, Human WHO Reference Reagent | 1EA |
| WY-NIBSC-99/710 | Anti-HIV 1 (1 in 5 BWS) | 1EA |
| WY-NIBSC-99/720 | Chorionic Gonadotrophin, alpha subunit, Human (purified) | 1EA |
| WY-NIBSC-99/750 | British Working Standard for Anti-HIV 1 | 1EA |
| WY-NIBSC-99/824 | Influenza Virus infectious RESVIR 16 (H3N2) | 1EA |
| WY-NIBSC-99/828 | Influenza Antigen B/Yamanashi/166/98 | 1EA |
| WY-NIBSC-99/836 | Anti-D Minimum Potency Standard for blood grouping reagents WHO International Standard | 1EA |
| WY-NIBSC-AFP | Alpha-Foetoprotein. WHO International Standard | 1EA |
| WY-NIBSC-BUSB | Botulinum Antitoxin Equine Type B. WHO International Standard | 1EA |
| WY-NIBSC-CDS | Anti-Canine Distemper Serum. WHO International Standard | 1EA |
| WY-NIBSC-CHAN | Cholera Antitoxin, Goat. WHO International Standard | 1EA |
| WY-NIBSC-CHS | Anti-Canine Hepatitis Serum | 1EA |
| WY-NIBSC-COT | Clostridium novyi (alpha) Toxoid. WHO Reference Reagent | 1EA |
| WY-NIBSC-CWBETATD | Clostridium Welchii (Perfringens)(Beta) Toxoid CwBT WHO Reference Reagent | 1EA |
| WY-NIBSC-CWEPSILTD | Clostridium Welchii (Perfringens) (Epsilon) toxoid | 1EA |
| WY-NIBSC-DIM9 | Diphtheria toxoid monoclonal antibody, clone Dim9 | 1EA |
| WY-NIBSC-DT05 | Diphtheria toxoid monoclonal antibody, clone DT05 | 1EA |
| WY-NIBSC-DY | Anti-Dysentery (shiga) serum, Equine. WHO International Standard | 1EA |
| WY-NIBSC-FHADETOX/6 | Filamentous Haemagglutinin monoclonal antibody, clone FHADETOX/6 | 1EA |
| WY-NIBSC-G10F8C3 | Fimbrae monoclonal antibody, clone G10F8C3 | 1EA |
| WY-NIBSC-HBOHA | Lyophilised HBO-HA Antigen for ELISA, Lot 17 | 1EA |
| WY-NIBSC-JNIH-11 | Bordetella pertussis anti FHA serum (mouse) | 1EA |
| WY-NIBSC-JNIH-12 | Bordetella pertussis PT( LPF) anti serum, (mouse) | 1EA |
| WY-NIBSC-JNIH-3 | Acellular Pertussis Vaccine - 1st IS | 1EA |
| WY-NIBSC-JNIH-4 | Bordetella pertussis filamentous haemagglutinin (FHA) | 1EA |
| WY-NIBSC-MGDS | Anti-Mycoplasma gallisepticum Serum. WHO Reference Reagent | 1EA |
| WY-NIBSC-NDS | Anti-Newcastle Disease Serum. WHO International Standard | 1EA |
| WY-NIBSC-NVIA | Newcastle Disease Vaccine (Inactivated) WHO International Standard | 1EA |
| WY-NIBSC-OE | Gas Gangrene Antitoxin (Cl. novyi), Equine WHO International Standard | 1EA |
| WY-NIBSC-PE | Gas Gangrene Antitoxin (Cl. Perfringens alpha antitoxin) Equine WHO International Standard | 1EA |
| WY-NIBSC-PPDBOV | Purified Protein Derivative (PPD) of Mycobacterium bovis Tuberculin (WHO 1st International Standard) | 1EA |
| WY-NIBSC-PPDT | Purified Protein Derivative (PPD) of M. Tuberculosis Tuberculin WHO International Standard | 1EA |
| WY-NIBSC-PS21C2.2.1 | Pertussis toxoid monoclonal antibody, clone PS21C2.2.1 | 1EA |
| WY-NIBSC-QF | Anti-Q Fever Serum, Bovine WHO International Standard | 1EA |
| WY-NIBSC-RBT/16 | Thromboplastin, Rabbit, Plain 5th International Standard 2016 | 1EA |
| WY-NIBSC-RTF/16 | Thromboplastin, Human, Recombinant, Plain 5th International Standard 2016 | 1EA |
| WY-NIBSC-RUBI-1-94 | Anti-rubella Immunoglobulin, Human WHO International Standard | 1EA |
| WY-NIBSC-SES | Swine Erysipelas Serum (anti-N) WHO Reference Reagent | 1EA |
| WY-NIBSC-SFS | Anti-Swine Fever Serum WHO International Standard | 1EA |
| WY-NIBSC-SMV | Smallpox Vaccine WHO International Standard | 1EA |
| WY-NIBSC-SPDS-S2 | Anti-Salmonella Pullorum Serum (Std. Form S) WHO International Standard | 1EA |
| WY-NIBSC-SPDS-V | Anti-Salmonella Pullorum Serum (Variant Form V) WHO International Standard | 1EA |
| WY-NIBSC-SPLS | Anti-Staphylococcal P-V Leucocidin serum, Equine WHO Reference Reagent | 1EA |
| WY-NIBSC-STA | Staphylococcus Alpha Antitoxin, Equine WHO International Standard | 1EA |
| WY-NIBSC-STT | Diphtheria (Schick) Test Toxin WHO International Standard | 1EA |
| WY-NIBSC-TILI | Anti-tick borne encephalitis serum (Louping Ill) WHO International Standard | 1EA |
| WY-NIBSC-TISA | Anti-tick borne encephalitis serum (Sophyn & Absettarov) WHO International Standard | 1EA |
| WY-NIBSC-TT010 | Tetanus toxoid monoclonal antibody, clone TT010 | 1EA |
| WY-NIBSC-TYVK | Typhoid Vaccine (acetone-inactivated) WHO International Standard | 1EA |
| WY-NIBSC-TYVL | Typhoid Vaccine (heat-phenol-inactivated) WHO International Standard | 1EA |
| WY-NIBSC-VI | Gas Gangrene Antitoxin (Cl. Septicum), Equine WHO International Standard | 1EA |
| WY-NIBSC-W1004 | Anti-C complete blood typing serum,human WHO International Standard | 1EA |
| WY-NIBSC-W1005 | Anti-E complete blood typing serum, human WHO International Standard | 1EA |
| WY-NIBSC-W1007 | Anti-c Incomplete blood typing serum, human WHO International Standard | 1EA |
| WY-NIBSC-W1044 | Anti-Varicella zoster immunoglobulin WHO International Standard | 1EA |
| WY-NIBSC-W1062 | Anti smooth muscle(anti actin) autoantibody. WHO Reference Reagent | 1EA |
| WY-NIBSC-W1063 | Anti nuclear ribonucleoprotein(nRNP) autoantibody WHO Reference Reagent | 1EA |
| WY-NIBSC-W1064 | Anti-Nuclear factor serum,homogenous(66/233) | 1EA |
| WY-NIBSC-YF | Anti-Yellow Fever Serum, monkey WHO Reference Reagent | 1EA |
| WY-NIBSC-04/122 | Anti-Meningococcal Serosubtype P1.12 mAb | 1EA |
| WY-NIBSC-100978 | VeroE6/TMPRSS2 | 1EA |
| WY-NIBSC-101044 | SARS-CoV-2 Omicron (lineage B.1.1.529) | 1EA |
| WY-NIBSC-12/300 | Negative Control IVIG (for use with IVIG and Anti-D) | 1EA |
| WY-NIBSC-12/306 | Haemophilus Influenzae Polysaccharide Polyribosyl Ribitol Phosphate (PRP)(2nd International Standard) | 1EA |
| WY-NIBSC-13/256 | Influenza virus infectious. NYMC x-233 | 1EA |
| WY-NIBSC-15/298 | Influenza Virus Infectious B/Brisbane/46/2015 | 1EA |
| WY-NIBSC-16/B707 | QCREBVNEGQC1 | 1EA |
| WY-NIBSC-17/160 | Sabin Inactivated Polio Vaccine (sIPV) (WHO 1st international Standard) | 1EA |
| WY-NIBSC-18/206 | West Nile Virus - International Standard | 1EA |
| WY-NIBSC-22/240 | Anti-pneumococcal serotype 6B monoclonal antibody (clone 14-102GA3 ID10 1B10) | 1EA |
| WY-NIBSC-73/601 | Carcinoembryonic Antigen (CEA), Human (1st International Reference Preparation) | 1EA |
| WY-NIBSC-98/778 | Influenza Virus infectious A/Sichuan/346/98 (H3N2) | 1EA |
| WY-NIBSC-99/514 | Anti-PT S1 subunit Monoclonal Antibody (8G4) | 1EA |
上一篇：Acanthus Research代理---上海维亦特生物
下一篇：无
